<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Viruses</journal-id><journal-id journal-id-type="iso-abbrev">Viruses</journal-id><journal-id journal-id-type="pmc-domain-id">1559</journal-id><journal-id journal-id-type="pmc-domain">viruses</journal-id><journal-id journal-id-type="publisher-id">viruses</journal-id><journal-title-group><journal-title>Viruses</journal-title></journal-title-group><issn pub-type="epub">1999-4915</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11599064</article-id><article-id pub-id-type="pmcid-ver">PMC11599064.1</article-id><article-id pub-id-type="pmcaid">11599064</article-id><article-id pub-id-type="pmcaiid">11599064</article-id><article-id pub-id-type="pmid">39599909</article-id><article-id pub-id-type="doi">10.3390/v16111795</article-id><article-id pub-id-type="publisher-id">viruses-16-01795</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Beyond Antivirals: Alternative Therapies for Long COVID</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Livieratos</surname><given-names initials="A">Achilleas</given-names></name><xref rid="af1-viruses-16-01795" ref-type="aff">1</xref><xref rid="c1-viruses-16-01795" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gogos</surname><given-names initials="C">Charalambos</given-names></name><xref rid="af2-viruses-16-01795" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4289-9494</contrib-id><name name-style="western"><surname>Akinosoglou</surname><given-names initials="K">Karolina</given-names></name><xref rid="af2-viruses-16-01795" ref-type="aff">2</xref><xref rid="af3-viruses-16-01795" ref-type="aff">3</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Baz</surname><given-names initials="M">Mariana</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Baker</surname><given-names initials="B">Barbara</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Kumar</surname><given-names initials="P">Priti</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Lange</surname><given-names initials="U">Ulrike</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-viruses-16-01795"><label>1</label>Independent Researcher, 15238 Athens, Greece</aff><aff id="af2-viruses-16-01795"><label>2</label>Department of Medicine, University of Patras, 26504 Rio, Greece; <email>cgogos@med.upatras.gr</email> (C.G.); <email>akin@upatras.gr</email> (K.A.)</aff><aff id="af3-viruses-16-01795"><label>3</label>Department of Internal Medicine and Infectious Diseases, University General Hospital of Patras, 26504 Rio, Greece</aff><author-notes><corresp id="c1-viruses-16-01795"><label>*</label>Correspondence: <email>achilleas.livieratos@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>19</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="collection"><month>11</month><year>2024</year></pub-date><volume>16</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">475876</issue-id><elocation-id>1795</elocation-id><history><date date-type="received"><day>19</day><month>9</month><year>2024</year></date><date date-type="rev-recd"><day>15</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>18</day><month>11</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>19</day><month>11</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>28</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-29 03:25:37.017"><day>29</day><month>11</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2024 by the authors.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="viruses-16-01795.pdf"/><abstract><p>Long COVID or Post-Acute Sequelae of SARS-CoV-2 infection (PASC) is a condition characterized by numerous lingering symptoms that persist for weeks to months following the viral illness. While treatment for PASC is still evolving, several therapeutic approaches beyond traditional antiviral therapies are being investigated, such as immune-modulating agents, anti-inflammatory drugs, and various supportive interventions focusing at alleviating symptoms and enhancing recovery. We aimed to summarize the breadth of available evidence, identify knowledge gaps, and highlight promising non-antiviral therapies for Long COVID/PASC. We followed the framework of a scoping methodology by mapping existing evidence from a range of studies, including randomized clinical trials, observational research, and case series. Treatments evaluated include metformin, low-dose naltrexone (LDN), dexamethasone, statins, omega-3 fatty acids, L-arginine, and emerging therapies like intravenous immunoglobulin (IVIg) and therapeutic apheresis. Early findings suggest that metformin has the strongest clinical evidence, particularly from large phase 3 trials, while LDN and dexamethasone show potential based on observational studies. However, many treatments lack robust, large-scale trials. This review emphasizes the need for further research to confirm the efficacy of these treatments and guide clinical practice for Long COVID management.</p></abstract><kwd-group><kwd>long COVID</kwd><kwd>post-COVID condition</kwd><kwd>non-antiviral treatments</kwd><kwd>SARS-CoV-2</kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-viruses-16-01795"><title>1. Introduction</title><p>Many patients who have managed to recover from COVID-19 continue to face lingering symptoms well past the acute phase of the initial infection [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>]. Long COVID, defined as a postviral syndrome, persists for a minimum of 3 months following the viral illness [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>]. It may present in various forms, including ongoing, recurrent, or progressively worsening symptoms, and can have systemic implications [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>]. Symptoms include fatigue, cognitive impairment, shortness of breath, and a wide range of other systemic issues [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>]. Long COVID, affecting an estimated 10% to 30% of those infected, can occur in anyone&#8212;including individuals with mild or asymptomatic cases&#8212;though it is more commonly associated with a severe initial illness [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>,<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>]. The condition may also exacerbate pre-existing health problems and lead to significant functional impairment [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>]. These symptoms have not only impeded recovery for millions, but have also burdened healthcare systems globally, driving the urgent need for effective therapeutic interventions [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>]. Among these symptoms, neuro-Long COVID, characterized by cognitive difficulties and fatigue&#8212;commonly referred to as &#8220;brain fog&#8221;&#8212;is a prevalent and persistent aspect of Long COVID-19 syndrome [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01795" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01795" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01795" ref-type="bibr">7</xref>]. Approximately up to 30% of patients experience cognitive impairments, with nearly 46% reporting some type of memory disruption [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01795" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01795" ref-type="bibr">6</xref>,<xref rid="B7-viruses-16-01795" ref-type="bibr">7</xref>]. The persistence of these cognitive issues, lasting for months or even years, underscores the necessity for long-term follow-up and specialized interventions to manage the enduring neurological impacts of Long COVID.</p><p>Long COVID risk also varies across different populations, with certain groups facing higher vulnerability [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>]. Special populations at increased risk include the elderly, individuals with various co-morbidities, and immunocompromised patients [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>]. These groups often experience more severe symptoms and longer-lasting effects [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>]. Additionally, women and individuals with a history of autoimmune diseases may be more susceptible to developing Long COVID symptoms, including fatigue, cognitive dysfunction, and musculoskeletal pain [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>,<xref rid="B5-viruses-16-01795" ref-type="bibr">5</xref>,<xref rid="B6-viruses-16-01795" ref-type="bibr">6</xref>]. The persistent inflammation and immune dysregulation that accompany Long COVID appear to be independent of the SARS-CoV-2 variant, suggesting that, while the severity of acute illness may vary, the risk of developing Long COVID persists across all variants [<xref rid="B4-viruses-16-01795" ref-type="bibr">4</xref>]. Finally, the impact of vaccination on Long COVID risk is significant as there is reduced risk of developing Long COVID compared to unvaccinated individuals [<xref rid="B5-viruses-16-01795" ref-type="bibr">5</xref>]. Immunization reduces both the severity of acute infection as well as the probability of experiencing prolonged symptoms [<xref rid="B5-viruses-16-01795" ref-type="bibr">5</xref>].</p><p>Long COVID appears to be a multifactorial syndrome, with several mechanisms potentially contributing to its complex pathology [<xref rid="B1-viruses-16-01795" ref-type="bibr">1</xref>,<xref rid="B7-viruses-16-01795" ref-type="bibr">7</xref>]. Hypotheses under investigation include immune dysregulation, mitochondrial dysfunction, endothelial damage, persistent inflammation, autoimmunity, viral persistence, dysautonomia, and microbe dysregulation or dysbiosis [<xref rid="B7-viruses-16-01795" ref-type="bibr">7</xref>]. Chronic immune system alterations are a key feature of long COVID, with persistent activation of innate immune cells, exhausted T cells, and elevated levels of interferons (type I and III) lasting months after infection [<xref rid="B8-viruses-16-01795" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01795" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01795" ref-type="bibr">10</xref>]. This immune dysregulation suggests the body may fail to return to homeostasis post-infection, leading to prolonged symptoms [<xref rid="B8-viruses-16-01795" ref-type="bibr">8</xref>,<xref rid="B9-viruses-16-01795" ref-type="bibr">9</xref>,<xref rid="B10-viruses-16-01795" ref-type="bibr">10</xref>]. Mitochondrial dysfunction, likely driven by dormant viruses such as Epstein&#8211;Barr Virus (EBV), results in impaired energy metabolism, chronic fatigue, and exercise intolerance [<xref rid="B11-viruses-16-01795" ref-type="bibr">11</xref>,<xref rid="B12-viruses-16-01795" ref-type="bibr">12</xref>,<xref rid="B13-viruses-16-01795" ref-type="bibr">13</xref>,<xref rid="B14-viruses-16-01795" ref-type="bibr">14</xref>,<xref rid="B15-viruses-16-01795" ref-type="bibr">15</xref>]. In addition, endothelial dysfunction contributes to microvascular blood clotting and impaired oxygen delivery, which may increase the risk of long-term cardiovascular complications like deep vein thrombosis and pulmonary embolism [<xref rid="B16-viruses-16-01795" ref-type="bibr">16</xref>].</p><p>A persistent inflammatory response, characterized by elevated pro-inflammatory cytokines such as TNF, mirrors other conditions like myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and suggests that inflammation continues long after the acute phase of infection [<xref rid="B7-viruses-16-01795" ref-type="bibr">7</xref>]. Moreover, the presence of elevated autoantibodies targeting receptors such as ACE2 and &#946;2-adrenoceptors indicates that autoimmunity, possibly triggered by molecular mimicry during SARS-CoV-2 infection, could be contributing to the prolonged symptoms [<xref rid="B17-viruses-16-01795" ref-type="bibr">17</xref>,<xref rid="B18-viruses-16-01795" ref-type="bibr">18</xref>]. Viral persistence is another significant hypothesis, as SARS-CoV-2 proteins or RNA have been found in various tissues, potentially maintaining a reservoir that drives long-term symptoms [<xref rid="B19-viruses-16-01795" ref-type="bibr">19</xref>,<xref rid="B20-viruses-16-01795" ref-type="bibr">20</xref>].</p><p>Dysautonomia, often manifesting as postural orthostatic tachycardia syndrome (POTS), is frequently observed in these patients and may result from immune system dysregulation or direct viral effects on the autonomic nervous system, leading to symptoms such as dizziness, abnormal heart rate, and fatigue [<xref rid="B21-viruses-16-01795" ref-type="bibr">21</xref>]. Finally, gut microbiota disruption, or dysbiosis, has been noted in Long COVID, with reduced levels of beneficial bacteria and an increase in harmful species, contributing to both gastrointestinal and systemic symptoms, including fatigue and cognitive impairment [<xref rid="B22-viruses-16-01795" ref-type="bibr">22</xref>]. These multiple overlapping mechanisms highlight the complexity of Long COVID and its far-reaching impact on various organ systems.</p><p>Findings indicate that antiviral treatment, when administered early (within 5 days of symptom onset), significantly reduces the occurrence of PASC by 27.5% [<xref rid="B23-viruses-16-01795" ref-type="bibr">23</xref>]. Moreover, antiviral therapy also lowers the risk of PASC-related hospitalizations and death by 29.7% [<xref rid="B23-viruses-16-01795" ref-type="bibr">23</xref>]. This reduction suggests that antiviral drugs may effectively prevent the long-term persistence of the virus in the body, which has been hypothesized to contribute to the ongoing symptoms associated with Long COVID [<xref rid="B23-viruses-16-01795" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01795" ref-type="bibr">24</xref>]. Additionally, the use of antiviral drugs helps to reduce viral load, which could mitigate the prolonged inflammation and immune dysregulation seen in many Long COVID patients [<xref rid="B23-viruses-16-01795" ref-type="bibr">23</xref>,<xref rid="B24-viruses-16-01795" ref-type="bibr">24</xref>]. However, while these results are promising, non-antiviral therapies that target the previously identified molecular pathways have emerged also as potential treatment strategies [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>,<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>,<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>,<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>,<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>,<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>,<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>,<xref rid="B36-viruses-16-01795" ref-type="bibr">36</xref>,<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>,<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>,<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>,<xref rid="B40-viruses-16-01795" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01795" ref-type="bibr">41</xref>].</p><p>This review aims to synthesize the current evidence on non-antiviral treatments for Long COVID, highlighting potential therapeutic options and identifying areas where further research is urgently needed. Specifically, the goal is to evaluate the efficacy of different treatments in addressing the multifaceted symptoms of Long COVID based on their clinical impact and feasibility of implementation. By examining and analyzing the available data, this study seeks to guide future clinical trials and provide insights for future evidence-based treatment guidelines for Long COVID, offering hope to the millions of patients suffering from this debilitating condition.</p></sec><sec id="sec2-viruses-16-01795"><title>2. Materials and Methods</title><p>Between January 2021 and September 2024, a comprehensive literature review was performed using PubMed, which initially identified 2032 potentially relevant articles. The search involved the following query: COVID-19 treatment OR Management AND Long COVID AND Post-acute sequela of SARS-CoV-2 (PASC) AND Post-COVID-19 condition (PCC) OR Syndrome. 1900 papers were excluded for being out of scope or involving animal research. Only English-language studies were considered, with duplicates removed. A detailed evaluation of the remaining 132 articles led to the removal of 114 studies due to their focus on anti-viral or combination treatment. Ultimately, 18 studies met the inclusion criteria (<xref rid="viruses-16-01795-f001" ref-type="fig">Figure 1</xref>). Two researchers reviewed and hand-searched the literature, resolving any disagreements collaboratively.</p><p>Among the 18 articles evaluated, design and patient number variations were significant between different studies. Collectively, these articles aimed to capture the diversity of different non-antiviral treatments investigated for Long COVID patients. Furthermore, advanced, in-progress pharmacotherapy trials (n = 7) for Long COVID patients are listed in a separate table. This includes phase 3&#8211;4 trials, with estimated trial completion dates prior to 2026, and the following search strings were applied when searching the Clinical Trials platform: Long COVID, Post-COVID Syndrome, Post-COVID Condition, and Post-acute sequela of SARS-CoV-2.</p></sec><sec sec-type="results" id="sec3-viruses-16-01795"><title>3. Results</title><p>In total, 18 studies were identified across seven therapeutic categories regarding available treatments (<xref rid="viruses-16-01795-t001" ref-type="table">Table 1</xref>). The Antihypertensive/ADHD Treatment category included one study, an open-label clinical experience involving guanfacine. The Antioxidant category included one phase 2 RCT and one observational study involving Coenzyme Q10. The Antidiabetic category comprised two phase 3 RCTs investigating metformin for reducing Long COVID risk. The Immunomodulator category had the largest number of studies, with eight in total, focusing on drugs such as low-dose naltrexone (LDN), dexamethasone, and intravenous immunoglobulins (IVIg), primarily through retrospective observational and case&#8211;control studies. The Statin category featured one observational study investigating atorvastatin/rosuvastatin. Lastly, the Other category included four observational studies examining interventions like omega-3, L-arginine + vitamin C, and therapeutic apheresis.</p><p>Among the ongoing trials, seven studies were identified across various therapeutic categories targeting Long COVID (<xref rid="viruses-16-01795-t002" ref-type="table">Table 2</xref>). The Immunomodulator category includes three studies: Anakinra, Ibudilast, Pentoxifylline, and Infliximab. These are primarily phase 2&#8211;3 randomized controlled trials (RCTs), except for the Infliximab study, which is a phase 4 randomized open-label trial. The Antidepressant category includes two studies: Fluvoxamine, and Fluvoxamine or Metformin, both of which are Phase 2&#8211;3 RCTs. The Other category includes two studies: one on ImmuneRecov, a Phase 3 non-randomized open label trial, and one on Testofen, a phase 3 RCT investigating its effects on energy and fatigue.</p></sec><sec sec-type="discussion" id="sec4-viruses-16-01795"><title>4. Discussion</title><p>Among the available treatments, metformin stands out with the strongest clinical evidence, due to two large phase 3 trials, which demonstrated substantial reductions in the incidence of Long COVID (42% to 63%) [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]. The high-quality design and consistent outcomes across large patient populations make metformin a leading candidate for preventing Long COVID. LDN also shows strong evidence, particularly in improving symptoms like fatigue, post-exertional malaise, and pain [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>]. Though most studies are observational, they involve relatively large patient cohorts, and the improvement metrics are significant, with a five-fold higher likelihood of improvement compared to physical therapy alone [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>]. Dexamethasone demonstrates clinically relevant reductions in fatigue and shortened symptom duration, with a 33% reduction in fatigue and a shorter median duration of symptoms (133 days vs. 271 days) [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>]. However, its observational study designs limit the strength of the evidence compared to metformin&#8217;s trials [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>]. Omega-3 fatty acids offer moderate improvements in mental health and musculoskeletal symptoms, such as depression and myalgia [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]. The large patient cohort (33,908 patients) adds weight to the findings, but the retrospective design reduces the quality of evidence [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]. Clinical outcomes are moderate but statistically significant [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]. L-Arginine, combined with vitamin C, shows compelling results, with 94.9% of patients reporting the absence of fatigue and 74.2% reporting no dyspnea [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>]. However, the study design (nationwide survey) limits the robustness of the findings [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>].</p><p>Several non-antiviral treatments for Long COVID show potential but are supported by lower-quality evidence compared to leading therapies like metformin, LDN, and dexamethasone. Therapeutic apheresis yielded significant improvements in 70% of 27 patients, with long-lasting symptom relief [<xref rid="B40-viruses-16-01795" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01795" ref-type="bibr">41</xref>]. Similarly, IVIg improved fatigue and cognitive dysfunction in 70&#8211;75% of patients in smaller studies [<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>]. NAC improved cognitive function in 67% of 12 patients but had a 25% discontinuation rate due to side effects [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>]. Despite some positive outcomes, these treatments need more robust studies to confirm their efficacy. <xref rid="viruses-16-01795-f002" ref-type="fig">Figure 2</xref> illustrates the impact of these different treatments on Long COVID patients.</p><sec id="sec4dot1-viruses-16-01795"><title>4.1. Alternative Therapies and Cognitive Impairment</title><p>The cognitive issues observed in individuals recovering from infection, including brain fog, PASC, and dysexecutive syndrome, are closely linked and commonly reported [<xref rid="B49-viruses-16-01795" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01795" ref-type="bibr">50</xref>]. Studies using electroencephalography have found that PASC patients often show decreased delta wave activity in brain regions involved in cognitive processing, which aligns with reduced performance on tasks requiring concentration and memory [<xref rid="B49-viruses-16-01795" ref-type="bibr">49</xref>]. Additionally, impairments in GABAergic circuits, especially within the primary motor cortex, have been noted in these patients, connecting these disruptions to both cognitive and physical fatigue [<xref rid="B50-viruses-16-01795" ref-type="bibr">50</xref>]. This ongoing neuroinflammatory activity appears to play a central role, not only in perpetuating cognitive deficits similar to those seen in dysexecutive syndrome but also in contributing to widespread dysregulation across brain networks, which is a characteristic of the brain fog frequently reported in these patients [<xref rid="B49-viruses-16-01795" ref-type="bibr">49</xref>,<xref rid="B50-viruses-16-01795" ref-type="bibr">50</xref>].</p><p>Guanfacine, an &#945;2A-adrenoceptor agonist, combined with the antioxidant N-acetylcysteine (NAC), has shown potential in addressing brain fog and related cognitive impairments [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>,<xref rid="B51-viruses-16-01795" ref-type="bibr">51</xref>]. Guanfacine works by strengthening prefrontal cortex connectivity, which is essential for processes such as working memory and concentration, both commonly affected in brain fog [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>,<xref rid="B51-viruses-16-01795" ref-type="bibr">51</xref>]. NAC, on the other hand, replenishes intracellular glutathione levels, protecting neurons from oxidative stress, which is often elevated in Long COVID [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>,<xref rid="B52-viruses-16-01795" ref-type="bibr">52</xref>].</p><p>Low-dose naltrexone (LDN), typically used for autoimmune disorders, has demonstrated benefits in reducing brain fog and fatigue in Long COVID. Through its immunomodulatory properties, LDN downregulates pro-inflammatory cytokines, helping to mitigate the chronic inflammation that often contributes to cognitive dysfunction [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>,<xref rid="B53-viruses-16-01795" ref-type="bibr">53</xref>]. Additionally, LDN&#8217;s effect on opioid receptors can positively impact mood and alleviate fatigue, creating a holistic improvement in patients&#8217; quality of life [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>,<xref rid="B53-viruses-16-01795" ref-type="bibr">53</xref>]. In studies, over 50% of participants reported cognitive improvements with LDN, although a small percentage discontinued due to mild side effects such as fatigue and gastrointestinal symptoms [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>].</p><p>Coenzyme Q10 (CoQ10) offers another promising approach by supporting mitochondrial function, often impaired in Long COVID [<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>,<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>]. As a critical element in mitochondrial energy production, CoQ10 helps alleviate symptoms of fatigue and muscle weakness, indirectly aiding cognitive recovery by enhancing physical endurance and reducing oxidative stress [<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>,<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>,<xref rid="B54-viruses-16-01795" ref-type="bibr">54</xref>]. While specific improvements in neurological symptoms were less pronounced, CoQ10 did show substantial fatigue reduction, which can positively impact cognitive function over time [<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>,<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>].</p><p>Intravenous immunoglobulin (IVIg) therapy has also demonstrated considerable effectiveness in treating brain fog in Long COVID patients [<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>]. IVIg works by neutralizing autoantibodies and modulating immune responses, effectively reducing the neuro-inflammation that contributes to cognitive dysfunction [<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>,<xref rid="B55-viruses-16-01795" ref-type="bibr">55</xref>]. This immune modulation helps alleviate fatigue, brain fog, and muscle weakness, restoring cognitive and physical function to a notable degree in many patients. Similarly, therapeutic apheresis has also shown promise by removing inflammatory cytokines, autoantibodies, and other pathogenic molecules from the blood, helping to reduce immune dysregulation and chronic inflammation that contribute to cognitive dysfunction [<xref rid="B40-viruses-16-01795" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01795" ref-type="bibr">41</xref>,<xref rid="B56-viruses-16-01795" ref-type="bibr">56</xref>].</p><p>Dexamethasone, a corticosteroid commonly used to reduce inflammation in acute COVID-19 cases, has shown potential in alleviating persistent symptoms of brain fog and fatigue in Long COVID. By dampening systemic inflammation and reducing pro-inflammatory cytokines, dexamethasone indirectly improves cognitive symptoms [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>,<xref rid="B57-viruses-16-01795" ref-type="bibr">57</xref>].</p><p>Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA), offer a supportive role in addressing inflammation-related symptoms such as mood and musculoskeletal pain, both of which can impact cognitive clarity [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>,<xref rid="B58-viruses-16-01795" ref-type="bibr">58</xref>]. EPA reduces inflammation through downregulating pro-inflammatory cytokines and enhancing endothelial function, thus supporting cardiovascular health and promoting better blood flow to the brain [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>,<xref rid="B58-viruses-16-01795" ref-type="bibr">58</xref>]. These effects contribute to modest cognitive improvements and reductions in depressive symptoms and muscle pain.</p><p>Metformin, an antidiabetic medication, has emerged as a preventative treatment for Long COVID symptoms, particularly when administered early [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>,<xref rid="B59-viruses-16-01795" ref-type="bibr">59</xref>]. Its anti-inflammatory properties and immune modulation effects reduce the risk of developing cognitive symptoms by addressing inflammation and oxidative stress at the onset of the disease [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]. When initiated early, it prevented the development of prolonged symptoms, indicating its strong protective potential against brain fog and related cognitive issues [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]. Lastly, L-arginine may help alleviate brain fog in Long COVID by increasing nitric oxide production, which improves blood circulation and brain oxygenation [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>,<xref rid="B60-viruses-16-01795" ref-type="bibr">60</xref>]. By enhancing endothelial function and reducing inflammation, L-arginine supports cognitive clarity and helps reduce associated fatigue [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>,<xref rid="B60-viruses-16-01795" ref-type="bibr">60</xref>]. <xref rid="viruses-16-01795-t003" ref-type="table">Table 3</xref> summarizes the impact of different therapies on cognitive impairment in Long COVID patients.</p></sec><sec id="sec4dot2-viruses-16-01795"><title>4.2. Alternative Therapies and Systemic Health Benefits</title><p>Guanfacine has been shown that it inhibits the replication of influenza virus by disrupting processes after viral protein synthesis, demonstrating a pleiotropic antiviral effect [<xref rid="B51-viruses-16-01795" ref-type="bibr">51</xref>]. Agonists like guanfacine showed broad-spectrum antiviral activity in vitro by reducing viral titers by up to 95%, although they did not directly reduce virus replication in vivo but improved survival by protecting against lung damage, such as edema [<xref rid="B51-viruses-16-01795" ref-type="bibr">51</xref>]. Similarly, NAC demonstrates pleiotropic effects against infections by modulating immune responses, reducing viral replication, and alleviating inflammation [<xref rid="B52-viruses-16-01795" ref-type="bibr">52</xref>]. In a study, 600 mg of oral NAC twice daily significantly reduced the occurrence of flu symptoms, with only 25% of infected individuals showing symptoms compared to 79% in the placebo group, highlighting its potential in reducing respiratory infections like COVID-19 [<xref rid="B52-viruses-16-01795" ref-type="bibr">52</xref>]. Together, guanfacine and NAC are believed to inhibit synergistically viral replication and thus reduce the occurrence of Long COVID [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>].</p><p>Clinical studies on naltrexone, originally used at higher doses to treat opioid addiction, have demonstrated that 4.5 mg of LDN daily resulted in a significant reduction in inflammatory markers and symptoms in chronic autoimmune conditions, where over 80% of participants showed improvement, demonstrating its broad therapeutic potential [<xref rid="B53-viruses-16-01795" ref-type="bibr">53</xref>]. Its proposed mechanisms include the upregulation of endogenous opioid receptors, which can have a beneficial impact on pain and mood disturbances commonly experienced in Long COVID [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>,<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>,<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>,<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>].</p><p>CoQ10 as an important antioxidant exhibits pleiotropic functions by also reducing inflammation, which is a critical factor in the progression of infectious diseases [<xref rid="B54-viruses-16-01795" ref-type="bibr">54</xref>]. In clinical trials, supplementation of 200 mg/day of CoQ10 significantly reduced TNF-&#945; inflammatory marker, and improved survival in sepsis patients, demonstrating its potential as an adjunct therapy in managing infections [<xref rid="B54-viruses-16-01795" ref-type="bibr">54</xref>]. By improving mitochondrial respiration and reducing oxidative damage, CoQ10 may help alleviate these symptoms, although more research is needed to fully elucidate its role in Long COVID treatment [<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>,<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>].</p><p>IVIg are immunomodulatory agents composed of pooled antibodies from healthy donors. Five day administration of high-dose IVIg has led to significant clinical improvement in COVID-19 patients, including normalization of oxygen saturation and reduction in inflammatory markers, with all patients recovering from severe symptoms [<xref rid="B55-viruses-16-01795" ref-type="bibr">55</xref>]. IVIg is also thought to have broader immunoregulatory effects, such as the inhibition of pro-inflammatory chemokines as well as the adaptation of immune cellular activity, making it a promising treatment for autoimmune-related components of Long COVID [<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>,<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>].</p><p>Therapeutic apheresis as a treatment approach is designed to eliminate harmful substances from the plasma, such as autoantibodies, inflammatory cytokines, lipids, and oxidative molecules [<xref rid="B40-viruses-16-01795" ref-type="bibr">40</xref>,<xref rid="B41-viruses-16-01795" ref-type="bibr">41</xref>]. In clinical studies, therapeutic plasma exchange reduced 28-day mortality by 20.5% in severe sepsis patients, while other extracorporeal techniques, such as high-volume hemofiltration and hemoadsorption, showed significant reductions in inflammatory markers, though without consistent survival benefits [<xref rid="B56-viruses-16-01795" ref-type="bibr">56</xref>]. Despite being invasive and costly, therapeutic apheresis may offer a novel approach to managing severe cases of Long COVID.</p><p>Although primarily used for managing severe acute COVID-19, there is interest in the potential for dexamethasone to reduce the long-term inflammation associated with Long COVID [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>]. In clinical trials, dexamethasone administration lowered mortality by 12.3% in patients on invasive mechanical ventilation and by 4.2% in those on oxygen support, highlighting its significant benefit in severe respiratory cases [<xref rid="B57-viruses-16-01795" ref-type="bibr">57</xref>]. By dampening the inflammatory cascade that may contribute to chronic symptoms, dexamethasone could help alleviate persistent respiratory issues and other inflammatory sequelae [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>,<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>].</p><p>Omega-3 fatty acids, due to their anti-inflammatory mechanism of action, have been proposed as a treatment for Long COVID to modulate chronic inflammation and improve endothelial function [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]. Additionally, omega-3 fatty acids may enhance cardiovascular health by improving endothelial function and reducing the risk of thrombosis, both of which are relevant to the vascular complications seen in Long COVID [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]. In a study of 100 hospitalized COVID-19 patients, those with higher omega-3 index levels (&#8805;5.7%) had a 75% lower risk of death compared to those with lower levels [<xref rid="B58-viruses-16-01795" ref-type="bibr">58</xref>].</p><p>Metformin improves insulin sensitivity, reduces oxidative stress, and modulates immune function [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]. Additionally, metformin&#8217;s role in reducing the risk of cardiovascular events could be beneficial for patients experiencing vascular complications as part of their Long COVID presentation [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>,<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]. Metformin exhibits pleiotropic effects due to anti-inflammatory activity and inhibition of viral replication [<xref rid="B59-viruses-16-01795" ref-type="bibr">59</xref>]. In a study of diabetic patients with influenza A virus, metformin administration decreased influenza-related mortality by 62% [<xref rid="B59-viruses-16-01795" ref-type="bibr">59</xref>].</p><p>L-arginine, classified as a conditionally indispensable amino acid, plays a pivotal role as the biochemical precursor to nitric oxide [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>]. L-arginine demonstrates pleiotropic effects in combating infections, particularly in COVID-19 patients, by reducing inflammation and improving endothelial function [<xref rid="B60-viruses-16-01795" ref-type="bibr">60</xref>]. In a randomized clinical trial, L-arginine supplementation significantly decreased the need for respiratory support by 82% after 10 days and reduced hospital stays from 36 to 22 days, while also lowering pro-inflammatory cytokines like IL-6 and increasing anti-inflammatory IL-10 [<xref rid="B60-viruses-16-01795" ref-type="bibr">60</xref>]. L-arginine supplementation in Long COVID patients may potentially improve endothelial function and enhance blood flow, particularly in patients with symptoms related to cardiovascular or respiratory dysfunction [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>].</p><p>Statins, widely known for their cholesterol-lowering properties, have garnered attention for their potential to mitigate cardiovascular complications in Long COVID patients [<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>]. Beyond their lipid-regulating effects, statins possess anti-inflammatory and immunomodulatory properties that may reduce the systemic inflammation associated with COVID-19. In a large retrospective study involving 13,981 participants, it was demonstrated that in-hospital statin use reduced all-cause mortality by 42%, highlighting their potential to improve outcomes in severe infections [<xref rid="B61-viruses-16-01795" ref-type="bibr">61</xref>,<xref rid="B62-viruses-16-01795" ref-type="bibr">62</xref>]. Statins appear to decrease the rate of major adverse cardiovascular events (MACE) in Long COVID patients [<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>]. Interestingly, maraviroc, a CCR5 antagonist, and pravastatin, a statin-targeting fractalkine, have also been investigated as a combination therapy for Long COVID [<xref rid="B36-viruses-16-01795" ref-type="bibr">36</xref>]. Participants reported a significant reduction in the fatigue severity score as well as reductions in inflammatory biomarkers, such as IL-2 [<xref rid="B36-viruses-16-01795" ref-type="bibr">36</xref>]. By stabilizing atherosclerotic plaques and modulating the immune response, statins help prevent cardiovascular complications that are exacerbated by COVID-19&#8242;s pro-inflammatory state [<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>]. Furthermore, their ability to reduce oxidative stress and endothelial dysfunction may improve overall vascular health, contributing to a reduction in fatigue, muscle weakness, and cognitive impairment in Long COVID patients [<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>].</p></sec><sec id="sec4dot3-viruses-16-01795"><title>4.3. Emerging Treatments</title><p>Emerging treatments for Long COVID focus on targeting chronic inflammation, immune dysregulation, and hormonal imbalances associated with the condition. Anakinra, an IL-1 receptor antagonist, helps reduce systemic inflammation, potentially alleviating symptoms like fatigue [<xref rid="B63-viruses-16-01795" ref-type="bibr">63</xref>,<xref rid="B64-viruses-16-01795" ref-type="bibr">64</xref>,<xref rid="B65-viruses-16-01795" ref-type="bibr">65</xref>]. It has previously been reported that 25% of COVID-19 patients of the anakinra group resulted in severe clinical outcomes or mortality versus the 73% in the control group, representing a significant reduction in risk [<xref rid="B66-viruses-16-01795" ref-type="bibr">66</xref>]. Fluvoxamine, an SSRI with anti-inflammatory properties, could address both lingering inflammation and neuropsychiatric symptoms such as brain fog [<xref rid="B67-viruses-16-01795" ref-type="bibr">67</xref>,<xref rid="B68-viruses-16-01795" ref-type="bibr">68</xref>]. In the TOGETHER trial, fluvoxamine administration reduced the risk of hospitalization or extended emergency care by 32%, resulting in a relative risk of 0.68 [<xref rid="B69-viruses-16-01795" ref-type="bibr">69</xref>]. Infliximab, a TNF inhibitor, is being explored for its potential to modulate the immune response, while Testofen, known for its testosterone-boosting effects, may alleviate fatigue and muscle weakness linked to hormonal imbalances [<xref rid="B70-viruses-16-01795" ref-type="bibr">70</xref>,<xref rid="B71-viruses-16-01795" ref-type="bibr">71</xref>]. An infliximab/tocilizumab combination reduced mortality rates to 7%, compared to 14.2% in the tocilizumab-only group and 42.5% in the standard treatment group, while also significantly lowering the need for mechanical ventilation and ICU admissions of COVID-19 patients [<xref rid="B72-viruses-16-01795" ref-type="bibr">72</xref>]. Low testosterone has also resulted in an increased mortality risk and ICU admission rate, and hypogonadism was prevalent in 89.8% of male patients, highlighting testosterone&#8217;s potential role in modulating immune response and inflammation during infections [<xref rid="B73-viruses-16-01795" ref-type="bibr">73</xref>]. Pentoxifylline, with its anti-inflammatory and vasodilatory properties, shows promise in addressing circulatory issues and systemic inflammation [<xref rid="B74-viruses-16-01795" ref-type="bibr">74</xref>]. In a study involving severe COVID-19 patients, pentoxifylline reduced lactate dehydrogenase by around 30% while it increased lymphocyte levels by over 60%, indicating its potential to alleviate hyperinflammation and improve immune response [<xref rid="B75-viruses-16-01795" ref-type="bibr">75</xref>]. Finally, ImmuneRecov&#8482;, a nutritional blend, has demonstrated potential in modulating immune responses and managing cytokine-mediated damage in Long COVID patients [<xref rid="B76-viruses-16-01795" ref-type="bibr">76</xref>]. The blend significantly reduced pro-inflammatory cytokines, such as IL-6, while increasing anti-inflammatory IL-10, suggesting that it helps modulate cytokine levels and counteract the hyperactivation caused by SARS-CoV-2, potentially reducing COVID-19 progression and sequelae [<xref rid="B76-viruses-16-01795" ref-type="bibr">76</xref>].</p><p>Vitamin D (VD), through its interaction with the vitamin D receptor (VDR), has been shown to modulate both the innate and adaptive immune systems, which is critical in combating respiratory viruses like SARS-CoV-2 [<xref rid="B77-viruses-16-01795" ref-type="bibr">77</xref>]. Vitamin D plays a role in regulating autophagy, reducing inflammatory cytokine production, and promoting the clearance of viral particles through immune system enhancement [<xref rid="B78-viruses-16-01795" ref-type="bibr">78</xref>,<xref rid="B79-viruses-16-01795" ref-type="bibr">79</xref>,<xref rid="B80-viruses-16-01795" ref-type="bibr">80</xref>]. For instance, a retrospective study involving 2342 hospitalized COVID-19 patients found that serum 25-hydroxyvitamin D deficiency was strongly correlated with a poorer prognosis, including increased mortality and longer ICU stays [<xref rid="B77-viruses-16-01795" ref-type="bibr">77</xref>,<xref rid="B81-viruses-16-01795" ref-type="bibr">81</xref>]. In terms of Long COVID, some observational studies reported that patients with persistent post-COVID symptoms tended to have lower VD levels than those who recovered without complications [<xref rid="B82-viruses-16-01795" ref-type="bibr">82</xref>,<xref rid="B83-viruses-16-01795" ref-type="bibr">83</xref>]. For instance, a case&#8211;control study with 50 Long COVID patients and 50 control subjects found significantly lower VD levels in the Long COVID group, suggesting a potential role for supplementation in preventing or alleviating these prolonged symptoms [<xref rid="B82-viruses-16-01795" ref-type="bibr">82</xref>,<xref rid="B83-viruses-16-01795" ref-type="bibr">83</xref>]. Overall, Vitamin D supplementation shows promise for improving outcomes in COVID-19 and Long COVID patients, particularly in those with deficient baseline levels [<xref rid="B84-viruses-16-01795" ref-type="bibr">84</xref>,<xref rid="B85-viruses-16-01795" ref-type="bibr">85</xref>].</p><p>Melatonin is a potent antioxidant and anti-inflammatory agent, with demonstrated immunomodulatory properties [<xref rid="B86-viruses-16-01795" ref-type="bibr">86</xref>,<xref rid="B87-viruses-16-01795" ref-type="bibr">87</xref>]. Furthermore, its role as a chronobiotic is crucial in restoring circadian rhythms, which can be disrupted in Long COVID, particularly for patients experiencing sleep disturbances or cognitive dysfunction [<xref rid="B88-viruses-16-01795" ref-type="bibr">88</xref>,<xref rid="B89-viruses-16-01795" ref-type="bibr">89</xref>,<xref rid="B90-viruses-16-01795" ref-type="bibr">90</xref>]. Quantitatively, melatonin has been shown to improve cognitive function in other neurodegenerative diseases [<xref rid="B86-viruses-16-01795" ref-type="bibr">86</xref>,<xref rid="B91-viruses-16-01795" ref-type="bibr">91</xref>,<xref rid="B92-viruses-16-01795" ref-type="bibr">92</xref>,<xref rid="B93-viruses-16-01795" ref-type="bibr">93</xref>,<xref rid="B94-viruses-16-01795" ref-type="bibr">94</xref>,<xref rid="B95-viruses-16-01795" ref-type="bibr">95</xref>]. For instance, a retrospective analysis of patients with mild cognitive impairment treated with melatonin showed significant improvements in cognitive performance, with reductions in depression and better sleep/wake rhythms [<xref rid="B91-viruses-16-01795" ref-type="bibr">91</xref>,<xref rid="B92-viruses-16-01795" ref-type="bibr">92</xref>,<xref rid="B93-viruses-16-01795" ref-type="bibr">93</xref>,<xref rid="B94-viruses-16-01795" ref-type="bibr">94</xref>,<xref rid="B95-viruses-16-01795" ref-type="bibr">95</xref>]. While direct clinical trials on Long COVID are limited, melatonin has shown measurable benefits in other conditions that share symptoms with Long COVID [<xref rid="B94-viruses-16-01795" ref-type="bibr">94</xref>,<xref rid="B95-viruses-16-01795" ref-type="bibr">95</xref>]</p></sec><sec id="sec4dot4-viruses-16-01795"><title>4.4. Limitations</title><p>This review is subject to several limitations that should be considered when interpreting the findings. First, there is significant heterogeneity among the included studies in terms of design, patient populations, and outcomes, which complicates direct comparisons and limits the generalizability of the results. Second, many of the interventions reviewed are supported by observational studies or small-scale trials, which reduces the strength of the evidence and underscores the need for larger, well-designed RCTs to validate these treatments. Third, the focus of most studies was on short- to mid-term outcomes, with limited data on long-term efficacy, a crucial factor for assessing the sustainability of therapeutic benefits in Long COVID management. Finally, as Long COVID is an emerging condition with evolving clinical understanding, the conclusions drawn from the current body of research may be influenced by new discoveries or viral variants, which could alter the treatment landscape and the applicability of these findings over time.</p></sec></sec><sec sec-type="conclusions" id="sec5-viruses-16-01795"><title>5. Conclusions</title><p>The management of Long COVID remains a complex and evolving challenge. This study highlights several promising therapeutic approaches, with metformin emerging as a leading candidate for both the prevention and management of this chronic condition due to its demonstrated efficacy in large, high-quality randomized trials. LDN also shows significant potential, particularly in alleviating symptoms such as fatigue and post-exertional malaise, although most evidence comes from observational studies. Other treatments, including omega-3 fatty acids and emerging therapies such as IVIg and therapeutic apheresis, offer moderate improvements but require further validation through larger, well-designed clinical trials. While antiviral treatments can reduce the progression of Long COVID symptoms if administered early, non-antiviral alternatives may provide broader symptom management by addressing immune dysregulation, inflammation, and other complex pathophysiological aspects associated with Long COVID. The non-antiviral therapies, particularly those addressing immune and inflammatory responses, emerge as valuable for comprehensive management of Long COVID, potentially complementing or enhancing the effects of antiviral treatments, thereby offering a multi-faceted approach that goes beyond early viral suppression.</p><p>Given the evolving nature of the pandemic and appearance of new viral strains, future research should also focus on the long-term health impacts of Long COVID and the effectiveness of these therapies across different viral strains and patient demographics. This is particularly important for high-risk individuals, such as the immunocompromised, and patients with pre-existing co-morbidities, to ensure that treatment strategies can be adapted to address their specific needs.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>K.A. and A.L. conceived the idea; A.L., K.A., and C.G. performed the literature search; A.L. wrote the manuscript and drew the figures; K.A. and C.G. critically corrected the manuscript; K.A. oversaw the study. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-viruses-16-01795"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ely</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Fineberg</surname><given-names>H.V.</given-names></name></person-group><article-title>Long Covid Defined</article-title><source>N. Engl. J. Med.</source><year>2024</year><volume>391</volume><fpage>1746</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1056/NEJMsb2408466</pub-id><pub-id pub-id-type="pmid">39083764</pub-id><pub-id pub-id-type="pmcid">PMC11687645</pub-id></element-citation></ref><ref id="B2-viruses-16-01795"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fesharaki-Zadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>N.</given-names></name><name name-style="western"><surname>Arnsten</surname><given-names>A.F.T.</given-names></name></person-group><article-title>Clinical Experience with the &#945;2A-adrenoceptor Agonist, Guanfacine, and N-acetylcysteine for the Treatment of Cognitive Deficits in &#8220;Long-COVID19&#8221;</article-title><source>Neuroimmunol. Rep.</source><year>2023</year><volume>3</volume><elocation-id>100154</elocation-id><pub-id pub-id-type="doi">10.1016/j.nerep.2022.100154</pub-id></element-citation></ref><ref id="B3-viruses-16-01795"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Mogensen</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Agergaard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schi&#248;ttz-Christensen</surname><given-names>B.</given-names></name><name name-style="western"><surname>&#216;stergaard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vibholm</surname><given-names>L.K.</given-names></name><name name-style="western"><surname>Leth</surname><given-names>S.</given-names></name></person-group><article-title>High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: A randomized, phase 2, crossover trial</article-title><source>Lancet Reg. Health Eur.</source><year>2023</year><volume>24</volume><elocation-id>100539</elocation-id><pub-id pub-id-type="doi">10.1016/j.lanepe.2022.100539</pub-id><pub-id pub-id-type="pmid">36337437</pub-id><pub-id pub-id-type="pmcid">PMC9627534</pub-id></element-citation></ref><ref id="B4-viruses-16-01795"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livieratos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gogos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Akinosoglou</surname><given-names>K.</given-names></name></person-group><article-title>SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>1222</elocation-id><pub-id pub-id-type="doi">10.3390/v16081222</pub-id><pub-id pub-id-type="pmid">39205196</pub-id><pub-id pub-id-type="pmcid">PMC11359867</pub-id></element-citation></ref><ref id="B5-viruses-16-01795"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Livieratos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gogos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Akinosoglou</surname><given-names>K.</given-names></name></person-group><article-title>Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>685</elocation-id><pub-id pub-id-type="doi">10.3390/v16050685</pub-id><pub-id pub-id-type="pmid">38793566</pub-id><pub-id pub-id-type="pmcid">PMC11125779</pub-id></element-citation></ref><ref id="B6-viruses-16-01795"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dietz</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Brondstater</surname><given-names>K.N.</given-names></name></person-group><article-title>Long COVID management: A mini review of current recommendations and underutilized modalities</article-title><source>Front. Med.</source><year>2024</year><volume>11</volume><elocation-id>1430444</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2024.1430444</pub-id><pub-id pub-id-type="pmcid">PMC11211541</pub-id><pub-id pub-id-type="pmid">38947233</pub-id></element-citation></ref><ref id="B7-viruses-16-01795"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davis</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>McCorkell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Topol</surname><given-names>E.J.</given-names></name></person-group><article-title>Long COVID: Major findings, mechanisms and recommendations</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00846-2</pub-id><pub-id pub-id-type="pmid">36639608</pub-id><pub-id pub-id-type="pmcid">PMC9839201</pub-id></element-citation></ref><ref id="B8-viruses-16-01795"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jaycox</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Dhodapkar</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gehlhausen</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Tabachnikova</surname><given-names>A.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tabacof</surname><given-names>L.</given-names></name><name name-style="western"><surname>Malik</surname><given-names>A.A.</given-names></name><etal/></person-group><article-title>Distinguishing features of long COVID identified through immune profiling</article-title><source>Nature</source><year>2023</year><volume>623</volume><fpage>139</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06651-y</pub-id><pub-id pub-id-type="pmid">37748514</pub-id><pub-id pub-id-type="pmcid">PMC10620090</pub-id></element-citation></ref><ref id="B9-viruses-16-01795"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynne</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tahmasebi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gant</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name></person-group><article-title>Long COVID following mild SARS-CoV-2 infection: Characteristic T cell alterations and response to antihistamines</article-title><source>J. Investig. Med.</source><year>2022</year><volume>70</volume><fpage>61</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1136/jim-2021-002051</pub-id><pub-id pub-id-type="pmcid">PMC8494538</pub-id><pub-id pub-id-type="pmid">34611034</pub-id></element-citation></ref><ref id="B10-viruses-16-01795"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phetsouphanh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Darley</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Howe</surname><given-names>A.</given-names></name><name name-style="western"><surname>Munier</surname><given-names>C.M.L.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Juno</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Burrell</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Dore</surname><given-names>G.J.</given-names></name><etal/></person-group><article-title>Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection</article-title><source>Nat. Immunol.</source><year>2022</year><volume>23</volume><fpage>210</fpage><lpage>216</lpage><pub-id pub-id-type="doi">10.1038/s41590-021-01113-x</pub-id><pub-id pub-id-type="pmid">35027728</pub-id></element-citation></ref><ref id="B11-viruses-16-01795"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guntur</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Nemkov</surname><given-names>T.</given-names></name><name name-style="western"><surname>de Boer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mohning</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Baraghoshi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cendali</surname><given-names>F.I.</given-names></name><name name-style="western"><surname>San-Mill&#225;n</surname><given-names>I.</given-names></name><name name-style="western"><surname>Petrache</surname><given-names>I.</given-names></name><name name-style="western"><surname>D&#8217;Alessandro</surname><given-names>A.</given-names></name></person-group><article-title>Signatures of Mitochondrial Dysfunction and Impaired Fatty Acid Metabolism in Plasma of Patients with Post-Acute Sequelae of COVID-19 (PASC)</article-title><source>Metabolites</source><year>2022</year><volume>12</volume><elocation-id>1026</elocation-id><pub-id pub-id-type="doi">10.3390/metabo12111026</pub-id><pub-id pub-id-type="pmid">36355108</pub-id><pub-id pub-id-type="pmcid">PMC9699059</pub-id></element-citation></ref><ref id="B12-viruses-16-01795"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az-Resendiz</surname><given-names>K.J.G.</given-names></name><name name-style="western"><surname>Benitez-Trinidad</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Covantes-Rosales</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Toledo-Ibarra</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Ortiz-Lazareno</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Gir&#243;n-P&#233;rez</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Bueno-Dur&#225;n</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>P&#233;rez-D&#237;az</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Barcelos-Garc&#237;a</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Gir&#243;n-P&#233;rez</surname><given-names>M.I.</given-names></name></person-group><article-title>Loss of mitochondrial membrane potential (&#916;&#936;(m)) in leucocytes as post-COVID-19 sequelae</article-title><source>J. Leukoc. Biol.</source><year>2022</year><volume>112</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1002/JLB.3MA0322-279RRR</pub-id><pub-id pub-id-type="pmid">35355308</pub-id><pub-id pub-id-type="pmcid">PMC9088601</pub-id></element-citation></ref><ref id="B13-viruses-16-01795"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pozzi</surname><given-names>A.</given-names></name></person-group><article-title>COVID-19 and Mitochondrial Non-Coding RNAs: New Insights From Published Data</article-title><source>Front. Physiol.</source><year>2021</year><volume>12</volume><elocation-id>805005</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2021.805005</pub-id><pub-id pub-id-type="pmid">35185603</pub-id><pub-id pub-id-type="pmcid">PMC8856670</pub-id></element-citation></ref><ref id="B14-viruses-16-01795"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paul</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Lemle</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Komaroff</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>S.H.</given-names></name></person-group><article-title>Redox imbalance links COVID-19 and myalgic encephalomyelitis/chronic fatigue syndrome</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2021</year><volume>118</volume><elocation-id>e2024358118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2024358118</pub-id><pub-id pub-id-type="pmid">34400495</pub-id><pub-id pub-id-type="pmcid">PMC8403932</pub-id></element-citation></ref><ref id="B15-viruses-16-01795"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zubchenko</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kril</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nadizhko</surname><given-names>O.</given-names></name><name name-style="western"><surname>Matsyura</surname><given-names>O.</given-names></name><name name-style="western"><surname>Chopyak</surname><given-names>V.</given-names></name></person-group><article-title>Herpesvirus infections and post-COVID-19 manifestations: A pilot observational study</article-title><source>Rheumatol. Int.</source><year>2022</year><volume>42</volume><fpage>1523</fpage><lpage>1530</lpage><pub-id pub-id-type="doi">10.1007/s00296-022-05146-9</pub-id><pub-id pub-id-type="pmid">35650445</pub-id><pub-id pub-id-type="pmcid">PMC9159383</pub-id></element-citation></ref><ref id="B16-viruses-16-01795"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Charfeddine</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ibn Hadj Amor</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jdidi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Torjmen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kraiem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hammami</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bahloul</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kallel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Moussa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Touil</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights from TUN-EndCOV Study</article-title><source>Front. Cardiovasc. Med.</source><year>2021</year><volume>8</volume><elocation-id>745758</elocation-id><pub-id pub-id-type="doi">10.3389/fcvm.2021.745758</pub-id><pub-id pub-id-type="pmid">34917659</pub-id><pub-id pub-id-type="pmcid">PMC8670225</pub-id></element-citation></ref><ref id="B17-viruses-16-01795"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wallukat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hohberger</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wenzel</surname><given-names>K.</given-names></name><name name-style="western"><surname>F&#252;rst</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schulze-Rothe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wallukat</surname><given-names>A.</given-names></name><name name-style="western"><surname>H&#246;nicke</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>M&#252;ller</surname><given-names>J.</given-names></name></person-group><article-title>Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms</article-title><source>J. Transl. Autoimmun.</source><year>2021</year><volume>4</volume><elocation-id>100100</elocation-id><pub-id pub-id-type="doi">10.1016/j.jtauto.2021.100100</pub-id><pub-id pub-id-type="pmid">33880442</pub-id><pub-id pub-id-type="pmcid">PMC8049853</pub-id></element-citation></ref><ref id="B18-viruses-16-01795"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.G.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Multiple early factors anticipate post-acute COVID-19 sequelae</article-title><source>Cell</source><year>2022</year><volume>185</volume><fpage>881</fpage><lpage>895.e20</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.01.014</pub-id><pub-id pub-id-type="pmid">35216672</pub-id><pub-id pub-id-type="pmcid">PMC8786632</pub-id></element-citation></ref><ref id="B19-viruses-16-01795"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tejerina</surname><given-names>F.</given-names></name><name name-style="western"><surname>Catalan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rodriguez-Grande</surname><given-names>C.</given-names></name><name name-style="western"><surname>Adan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rodriguez-Gonzalez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mu&#241;oz</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aldamiz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fanciulli</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Post-COVID-19 syndrome. SARS-CoV-2 RNA detection in plasma, stool, and urine in patients with persistent symptoms after COVID-19</article-title><source>BMC Infect. Dis.</source><year>2022</year><volume>22</volume><elocation-id>211</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-022-07153-4</pub-id><pub-id pub-id-type="pmid">35240997</pub-id><pub-id pub-id-type="pmcid">PMC8892394</pub-id></element-citation></ref><ref id="B20-viruses-16-01795"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ceulemans</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yoo</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Zapiec</surname><given-names>B.</given-names></name><name name-style="western"><surname>Van Gerven</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Slambrouck</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vanstapel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Raemdonck</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wauters</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Persistence of SARS-CoV-2 RNA in lung tissue after mild COVID-19</article-title><source>Lancet Respir. Med.</source><year>2021</year><volume>9</volume><fpage>e78</fpage><lpage>e79</lpage><pub-id pub-id-type="doi">10.1016/S2213-2600(21)00240-X</pub-id><pub-id pub-id-type="pmid">34118186</pub-id><pub-id pub-id-type="pmcid">PMC8189667</pub-id></element-citation></ref><ref id="B21-viruses-16-01795"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larsen</surname><given-names>N.W.</given-names></name><name name-style="western"><surname>Stiles</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Shaik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>L.</given-names></name><name name-style="western"><surname>Muppidi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tsui</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>H.</given-names></name><name name-style="western"><surname>Miglis</surname><given-names>M.G.</given-names></name></person-group><article-title>Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults</article-title><source>Front. Neurol.</source><year>2022</year><volume>13</volume><elocation-id>1012668</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2022.1012668</pub-id><pub-id pub-id-type="pmid">36353127</pub-id><pub-id pub-id-type="pmcid">PMC9639503</pub-id></element-citation></ref><ref id="B22-viruses-16-01795"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeoh</surname><given-names>Y.K.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lui</surname><given-names>G.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Li</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Tso</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Fung</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19</article-title><source>Gut</source><year>2021</year><volume>70</volume><fpage>698</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1136/gutjnl-2020-323020</pub-id><pub-id pub-id-type="pmid">33431578</pub-id><pub-id pub-id-type="pmcid">PMC7804842</pub-id></element-citation></ref><ref id="B23-viruses-16-01795"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Bin Seo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nham</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Effectiveness of Antiviral Therapy on Long COVID: A Systematic Review and Meta-Analysis</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>7375</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12237375</pub-id><pub-id pub-id-type="pmid">38068427</pub-id><pub-id pub-id-type="pmcid">PMC10707593</pub-id></element-citation></ref><ref id="B24-viruses-16-01795"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rahmah</surname><given-names>L.</given-names></name><name name-style="western"><surname>Abarikwu</surname><given-names>S.O.</given-names></name><name name-style="western"><surname>Arero</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Essouma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jibril</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Fal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Flisiak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Makuku</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marquez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Oral antiviral treatments for COVID-19: Opportunities and challenges</article-title><source>Pharmacol. Rep.</source><year>2022</year><volume>74</volume><fpage>1255</fpage><lpage>1278</lpage><pub-id pub-id-type="doi">10.1007/s43440-022-00388-7</pub-id><pub-id pub-id-type="pmid">35871712</pub-id><pub-id pub-id-type="pmcid">PMC9309032</pub-id></element-citation></ref><ref id="B25-viruses-16-01795"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barletta</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Marino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bianchi</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Falappone</surname><given-names>P.C.F.</given-names></name><name name-style="western"><surname>Spagnolo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gatti</surname><given-names>P.</given-names></name></person-group><article-title>Coenzyme Q10&#8201;+&#8201;alpha lipoic acid for chronic COVID syndrome</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>23</volume><fpage>667</fpage><lpage>678</lpage><pub-id pub-id-type="doi">10.1007/s10238-022-00871-8</pub-id><pub-id pub-id-type="pmid">35994177</pub-id><pub-id pub-id-type="pmcid">PMC9395797</pub-id></element-citation></ref><ref id="B26-viruses-16-01795"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bramante</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Beckman</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>T.</given-names></name><name name-style="western"><surname>Karger</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Odde</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Tignanelli</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Buse</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>R.H.B.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19</article-title><source>Clin. Infect. Dis.</source><year>2024</year><volume>79</volume><fpage>354</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1093/cid/ciae159</pub-id><pub-id pub-id-type="pmid">38690892</pub-id><pub-id pub-id-type="pmcid">PMC11327787</pub-id></element-citation></ref><ref id="B27-viruses-16-01795"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bramante</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Buse</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Liebovitz</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Nicklas</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Puskarich</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belani</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Huling</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Tignanelli</surname><given-names>C.J.</given-names></name><etal/></person-group><article-title>Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): A multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>1119</fpage><lpage>1129</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00299-2</pub-id><pub-id pub-id-type="pmid">37302406</pub-id><pub-id pub-id-type="pmcid">PMC11259948</pub-id></element-citation></ref><ref id="B28-viruses-16-01795"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonilla</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>L.</given-names></name><name name-style="western"><surname>Marconi</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>Shafer</surname><given-names>R.</given-names></name><name name-style="western"><surname>McComsey</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Miglis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bonilla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Eggert</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>L.N.</given-names></name></person-group><article-title>Low-dose naltrexone use for the management of post-acute sequelae of COVID-19</article-title><source>Int. Immunopharmacol.</source><year>2023</year><volume>124</volume><elocation-id>110966</elocation-id><pub-id pub-id-type="doi">10.1016/j.intimp.2023.110966</pub-id><pub-id pub-id-type="pmid">37804660</pub-id><pub-id pub-id-type="pmcid">PMC11028858</pub-id></element-citation></ref><ref id="B29-viruses-16-01795"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Isman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nyquist</surname><given-names>A.</given-names></name><name name-style="western"><surname>Strecker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harinath</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>V.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zalzala</surname><given-names>S.</given-names></name></person-group><article-title>Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19</article-title><source>Brain Behav. Immun. Health</source><year>2024</year><volume>36</volume><elocation-id>100733</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbih.2024.100733</pub-id><pub-id pub-id-type="pmid">38352659</pub-id><pub-id pub-id-type="pmcid">PMC10862402</pub-id></element-citation></ref><ref id="B30-viruses-16-01795"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tamariz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bast</surname><given-names>E.</given-names></name><name name-style="western"><surname>Klimas</surname><given-names>N.</given-names></name><name name-style="western"><surname>Palacio</surname><given-names>A.</given-names></name></person-group><article-title>Low-dose Naltrexone Improves post-COVID-19 condition Symptoms</article-title><source>Clin. Ther.</source><year>2024</year><volume>46</volume><fpage>e101</fpage><lpage>e106</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2023.12.009</pub-id><pub-id pub-id-type="pmid">38267326</pub-id></element-citation></ref><ref id="B31-viruses-16-01795"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Kelly</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vidal</surname><given-names>L.</given-names></name><name name-style="western"><surname>McHugh</surname><given-names>T.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Avramovic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lambert</surname><given-names>J.S.</given-names></name></person-group><article-title>Safety and efficacy of low dose naltrexone in a long covid cohort; an interventional pre-post study</article-title><source>Brain Behav. Immun. Health</source><year>2022</year><volume>24</volume><elocation-id>100485</elocation-id><pub-id pub-id-type="doi">10.1016/j.bbih.2022.100485</pub-id><pub-id pub-id-type="pmid">35814187</pub-id><pub-id pub-id-type="pmcid">PMC9250701</pub-id></element-citation></ref><ref id="B32-viruses-16-01795"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Milne</surname><given-names>A.</given-names></name><name name-style="western"><surname>Maskell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharp</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>D.T.</given-names></name></person-group><article-title>Impact of Dexamethasone on Persistent Symptoms of COVID-19: An Observational Study</article-title><source>Wellcome Open Res.</source><year>2023</year><volume>8</volume><elocation-id>145</elocation-id><pub-id pub-id-type="doi">10.12688/wellcomeopenres.18277.1</pub-id></element-citation></ref><ref id="B33-viruses-16-01795"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bonet</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>V&#233;lez</surname><given-names>O.A.C.</given-names></name><name name-style="western"><surname>Jord&#224;</surname><given-names>X.D.</given-names></name><name name-style="western"><surname>Serrano</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Admetll&#243;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Blasco</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Godia</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ezquerra</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>Treatment of COVID-19 during the Acute Phase in Hospitalized Patients Decreases Post-Acute Sequelae of COVID-19</article-title><source>J. Clin. Med.</source><year>2023</year><volume>12</volume><elocation-id>4158</elocation-id><pub-id pub-id-type="doi">10.3390/jcm12124158</pub-id><pub-id pub-id-type="pmid">37373850</pub-id><pub-id pub-id-type="pmcid">PMC10299438</pub-id></element-citation></ref><ref id="B34-viruses-16-01795"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hogeweg</surname><given-names>M.</given-names></name><name name-style="western"><surname>Doevelaar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rieckmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Seibert</surname><given-names>F.</given-names></name><name name-style="western"><surname>Scholten</surname><given-names>D.</given-names></name><name name-style="western"><surname>Segelmacher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Stervbo</surname><given-names>U.</given-names></name><name name-style="western"><surname>Babel</surname><given-names>N.</given-names></name><name name-style="western"><surname>Westhoff</surname><given-names>T.H.</given-names></name></person-group><article-title>Intravenous immunoglobulins in the treatment of post-COVID: A case-control study</article-title><source>J. Intern. Med.</source><year>2023</year><volume>293</volume><fpage>656</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1111/joim.13592</pub-id><pub-id pub-id-type="pmid">36414570</pub-id></element-citation></ref><ref id="B35-viruses-16-01795"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Thornton</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ainger</surname><given-names>T.</given-names></name><name name-style="western"><surname>Garvy</surname><given-names>B.A.</given-names></name></person-group><article-title>Long-term high-dose immunoglobulin successfully treats Long COVID patients with pulmonary, neurologic, and cardiologic symptoms</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><elocation-id>1033651</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.1033651</pub-id><pub-id pub-id-type="pmid">36818469</pub-id><pub-id pub-id-type="pmcid">PMC9932260</pub-id></element-citation></ref><ref id="B36-viruses-16-01795"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patterson</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Yogendra</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guevara-Coto</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mora-Rodriguez</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Osgood</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bream</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parikh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kreimer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jeffers</surname><given-names>D.</given-names></name><name name-style="western"><surname>Rutland</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)</article-title><source>Front. Med.</source><year>2023</year><volume>10</volume><elocation-id>1122529</elocation-id><pub-id pub-id-type="doi">10.3389/fmed.2023.1122529</pub-id><pub-id pub-id-type="pmcid">PMC9944830</pub-id><pub-id pub-id-type="pmid">36844201</pub-id></element-citation></ref><ref id="B37-viruses-16-01795"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khosravi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghodsi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Memarjafari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nematollahi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sheikh-Sharbafan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sadre-Bafghi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Moosavi</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Abdollahzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jalali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Farahani</surname><given-names>M.M.</given-names></name></person-group><article-title>Long-Term Major Adverse Cardiovascular Events in Patients with Moderate and Severe COVID-19: A Focus on Early Statin Use and Previous CVD</article-title><source>J. Tehran Univ. Heart Cent.</source><year>2023</year><volume>18</volume><fpage>183</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.18502/jthc.v18i3.14113</pub-id><pub-id pub-id-type="pmcid">PMC10748661</pub-id><pub-id pub-id-type="pmid">38146416</pub-id></element-citation></ref><ref id="B38-viruses-16-01795"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>P.Y.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>K.P.</given-names></name></person-group><article-title>Omega-3 polyunsaturated fatty acids and the psychiatric post-acute sequelae of COVID-19: A one-year retrospective cohort analysis of 33,908 patients</article-title><source>Brain Behav. Immun.</source><year>2023</year><volume>114</volume><fpage>453</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.bbi.2023.09.008</pub-id><pub-id pub-id-type="pmid">37716377</pub-id></element-citation></ref><ref id="B39-viruses-16-01795"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Izzo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trimarco</surname><given-names>V.</given-names></name><name name-style="western"><surname>Mone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Alo&#232;</surname><given-names>T.</given-names></name><name name-style="western"><surname>Marzani</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Diana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fazio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mallardo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maniscalco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Marazzi</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Combining L-Arginine with vitamin C improves long-COVID symptoms: The LINCOLN Survey</article-title><source>Pharmacol. Res.</source><year>2022</year><volume>183</volume><elocation-id>106360</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2022.106360</pub-id><pub-id pub-id-type="pmid">35868478</pub-id><pub-id pub-id-type="pmcid">PMC9295384</pub-id></element-citation></ref><ref id="B40-viruses-16-01795"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaeger</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Arron</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Booyens</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Kappert</surname><given-names>C.</given-names></name><name name-style="western"><surname>van Helden</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weimer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weing&#228;rtner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Seibel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reichl</surname><given-names>F.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Long Covid Patients Successfully Treated by Means of Heparin-Mediated Extracorporeal LDL Precipitation (H.E.L.P.)</article-title><source>Apheresis. Infect. Dis. Diagn. Treat.</source><year>2023</year><volume>7</volume><elocation-id>216</elocation-id><pub-id pub-id-type="doi">10.29011/2577-1515.100216</pub-id></element-citation></ref><ref id="B41-viruses-16-01795"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Achleitner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Steenblock</surname><given-names>C.</given-names></name><name name-style="western"><surname>D&#228;nhardt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jarzebska</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kardashi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kanczkowski</surname><given-names>W.</given-names></name><name name-style="western"><surname>Straube</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodionov</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Bornstein</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tselmin</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Clinical improvement of Long-COVID is associated with reduction in autoantibodies, lipids, and inflammation following therapeutic apheresis</article-title><source>Mol. Psychiatry</source><year>2023</year><volume>28</volume><fpage>2872</fpage><lpage>2877</lpage><pub-id pub-id-type="doi">10.1038/s41380-023-02084-1</pub-id><pub-id pub-id-type="pmid">37131073</pub-id><pub-id pub-id-type="pmcid">PMC10152027</pub-id></element-citation></ref><ref id="B42-viruses-16-01795"><label>42.</label><element-citation publication-type="gov"><article-title>Safety and Efficacy of Anakinra Treatment for Patients with Post Acute Covid Syndrome (PRECISION). ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05926505">NCT05926505</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05926505?cond=NCT05926505&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05926505?cond=NCT05926505&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B43-viruses-16-01795"><label>43.</label><element-citation publication-type="gov"><article-title>Reclaim: Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine (RECLAIM). ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05513560">NCT05513560</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05513560?cond=NCT05513560&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05513560?cond=NCT05513560&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B44-viruses-16-01795"><label>44.</label><element-citation publication-type="gov"><article-title>Solidarity Finland Plus Long-COVID. ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05220280">NCT05220280</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05220280" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05220280</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B45-viruses-16-01795"><label>45.</label><element-citation publication-type="gov"><article-title>Fluvoxamine for Long COVID-19. ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05874037">NCT05874037</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05874037?cond=NCT05874037&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05874037?cond=NCT05874037&amp;term=Long%20COVID&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B46-viruses-16-01795"><label>46.</label><element-citation publication-type="gov"><article-title>A Multicenter, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Study in Participants with Long COVID-19: The REVIVE Trial (REVIVE). ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06128967">NCT06128967</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06128967?cond=NCT06128967&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06128967?cond=NCT06128967&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B47-viruses-16-01795"><label>47.</label><element-citation publication-type="gov"><article-title>Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms. ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05795816">NCT05795816</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT05795816?cond=NCT05795816&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT05795816?cond=NCT05795816&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B48-viruses-16-01795"><label>48.</label><element-citation publication-type="gov"><article-title>Immunerecov Contributes to Improvement of Respiratory and Immunological Response in Post-COVID-19 Patients. (IRPC). ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06166030">NCT06166030</ext-link></article-title><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT06166030?cond=NCT06166030&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1" ext-link-type="uri">https://clinicaltrials.gov/study/NCT06166030?cond=NCT06166030&amp;limit=100&amp;aggFilters=status:rec&amp;rank=1</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2024-09-20">(accessed on 20 September 2024)</date-in-citation></element-citation></ref><ref id="B49-viruses-16-01795"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ortelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Quercia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cerasa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dezi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ferrazzoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sebastianelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Saltuari</surname><given-names>L.</given-names></name><name name-style="western"><surname>Versace</surname><given-names>V.</given-names></name><name name-style="western"><surname>Quartarone</surname><given-names>A.</given-names></name></person-group><article-title>Lowered Delta Activity in Post-COVID-19 Patients with Fatigue and Cognitive Impairment</article-title><source>Biomedicines</source><year>2023</year><volume>11</volume><elocation-id>2228</elocation-id><pub-id pub-id-type="doi">10.3390/biomedicines11082228</pub-id><pub-id pub-id-type="pmid">37626724</pub-id><pub-id pub-id-type="pmcid">PMC10452696</pub-id></element-citation></ref><ref id="B50-viruses-16-01795"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Versace</surname><given-names>V.</given-names></name><name name-style="western"><surname>Sebastianelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ferrazzoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Romanello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ortelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saltuari</surname><given-names>L.</given-names></name><name name-style="western"><surname>D&#8217;Acunto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Porrazzini</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ajello</surname><given-names>V.</given-names></name><name name-style="western"><surname>Oliviero</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Intracortical GABAergic dysfunction in patients with fatigue and dysexecutive syndrome after COVID-19</article-title><source>Clin. Neurophysiol.</source><year>2021</year><volume>132</volume><fpage>1138</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2021.03.001</pub-id><pub-id pub-id-type="pmid">33774378</pub-id><pub-id pub-id-type="pmcid">PMC7954785</pub-id></element-citation></ref><ref id="B51-viruses-16-01795"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Matsui</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ozawa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kiso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yamashita</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maekawa</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sugano</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Stimulation of alpha2-adrenergic receptors impairs influenza virus infection</article-title><source>Sci. Rep.</source><year>2018</year><volume>8</volume><elocation-id>4631</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-22927-0</pub-id><pub-id pub-id-type="pmid">29545586</pub-id><pub-id pub-id-type="pmcid">PMC5854622</pub-id></element-citation></ref><ref id="B52-viruses-16-01795"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Puyo</surname><given-names>C.A.</given-names></name></person-group><article-title>N-Acetylcysteine to Combat COVID-19: An Evidence Review</article-title><source>Ther. Clin. Risk Manag.</source><year>2020</year><volume>16</volume><fpage>1047</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.2147/TCRM.S273700</pub-id><pub-id pub-id-type="pmid">33177829</pub-id><pub-id pub-id-type="pmcid">PMC7649937</pub-id></element-citation></ref><ref id="B53-viruses-16-01795"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Younger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parkitny</surname><given-names>L.</given-names></name><name name-style="western"><surname>McLain</surname><given-names>D.</given-names></name></person-group><article-title>The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain</article-title><source>Clin. Rheumatol.</source><year>2014</year><volume>33</volume><fpage>451</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1007/s10067-014-2517-2</pub-id><pub-id pub-id-type="pmid">24526250</pub-id><pub-id pub-id-type="pmcid">PMC3962576</pub-id></element-citation></ref><ref id="B54-viruses-16-01795"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sifuentes-Franco</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#225;nchez-Mac&#237;as</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Carrillo-Ibarra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rivera-Vald&#233;s</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Zu&#241;iga</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>S&#225;nchez-L&#243;pez</surname><given-names>V.A.</given-names></name></person-group><article-title>Antioxidant and Anti-Inflammatory Effects of Coenzyme Q10 Supplementation on Infectious Diseases</article-title><source>Healthcare</source><year>2022</year><volume>10</volume><elocation-id>487</elocation-id><pub-id pub-id-type="doi">10.3390/healthcare10030487</pub-id><pub-id pub-id-type="pmid">35326965</pub-id><pub-id pub-id-type="pmcid">PMC8953254</pub-id></element-citation></ref><ref id="B55-viruses-16-01795"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>K.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>T.</given-names></name></person-group><article-title>High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019</article-title><source>Open Forum Infect. Dis.</source><year>2020</year><volume>7</volume><elocation-id>ofaa102</elocation-id><pub-id pub-id-type="doi">10.1093/ofid/ofaa102</pub-id><pub-id pub-id-type="pmid">32258207</pub-id><pub-id pub-id-type="pmcid">PMC7111600</pub-id></element-citation></ref><ref id="B56-viruses-16-01795"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klinkmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Altrichter</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Mitzner</surname><given-names>S.</given-names></name></person-group><article-title>Therapeutic apheresis in sepsis</article-title><source>Ther. Apher. Dial.</source><year>2022</year><volume>26</volume><fpage>64</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1111/1744-9987.13815</pub-id><pub-id pub-id-type="pmid">36468315</pub-id></element-citation></ref><ref id="B57-viruses-16-01795"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Emberson</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mafham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Linsell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Staplin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Brightling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ustianowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Elmahi</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Dexamethasone in Hospitalized Patients with Covid-19</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>384</volume><fpage>693</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id><pub-id pub-id-type="pmid">32678530</pub-id><pub-id pub-id-type="pmcid">PMC7383595</pub-id></element-citation></ref><ref id="B58-viruses-16-01795"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tintle</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lockshon</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bacareza</surname><given-names>H.</given-names></name><name name-style="western"><surname>Harris</surname><given-names>W.S.</given-names></name></person-group><article-title>Blood omega-3 fatty acids and death from COVID-19: A pilot study</article-title><source>Prostaglandins Leukot. Essent. Fat. Acids</source><year>2021</year><volume>166</volume><elocation-id>102250</elocation-id><pub-id pub-id-type="doi">10.1016/j.plefa.2021.102250</pub-id><pub-id pub-id-type="pmid">33516093</pub-id><pub-id pub-id-type="pmcid">PMC7816864</pub-id></element-citation></ref><ref id="B59-viruses-16-01795"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Noh</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Cheong</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>W.J.</given-names></name></person-group><article-title>Metformin reduces the risk of developing influenza A virus related cardiovascular disease</article-title><source>Heliyon</source><year>2023</year><volume>9</volume><elocation-id>e20284</elocation-id><pub-id pub-id-type="doi">10.1016/j.heliyon.2023.e20284</pub-id><pub-id pub-id-type="pmid">37810823</pub-id><pub-id pub-id-type="pmcid">PMC10556598</pub-id></element-citation></ref><ref id="B60-viruses-16-01795"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trimarco</surname><given-names>V.</given-names></name><name name-style="western"><surname>Izzo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lombardi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Coppola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fiorentino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Santulli</surname><given-names>G.</given-names></name></person-group><article-title>Beneficial effects of L-Arginine in patients hospitalized for COVID-19: New insights from a randomized clinical trial</article-title><source>Pharmacol. Res.</source><year>2023</year><volume>191</volume><elocation-id>106702</elocation-id><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106702</pub-id><pub-id pub-id-type="pmid">36804278</pub-id><pub-id pub-id-type="pmcid">PMC9928676</pub-id></element-citation></ref><ref id="B61-viruses-16-01795"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Daniels</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Sitapati</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bui</surname><given-names>Q.M.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>J.</given-names></name><name name-style="western"><surname>Longhurst</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Criqui</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Messer</surname><given-names>K.</given-names></name></person-group><article-title>Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients</article-title><source>Am. J. Cardiol.</source><year>2020</year><volume>136</volume><fpage>149</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1016/j.amjcard.2020.09.012</pub-id><pub-id pub-id-type="pmid">32946859</pub-id><pub-id pub-id-type="pmcid">PMC7492151</pub-id></element-citation></ref><ref id="B62-viruses-16-01795"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.J.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19</article-title><source>Cell Metab.</source><year>2020</year><volume>32</volume><fpage>176</fpage><lpage>187.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2020.06.015</pub-id><pub-id pub-id-type="pmid">32592657</pub-id><pub-id pub-id-type="pmcid">PMC7311917</pub-id></element-citation></ref><ref id="B63-viruses-16-01795"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akinosoglou</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kotsaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gounaridi</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Christaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Metallidis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adamis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fragkou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fantoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rapti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kalomenidis</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Efficacy and safety of early soluble urokinase plasminogen receptor plasma-guided anakinra treatment of COVID-19 pneumonia: A subgroup analysis of the SAVE-MORE randomised trial</article-title><source>EClinicalMedicine</source><year>2023</year><volume>56</volume><elocation-id>101785</elocation-id><pub-id pub-id-type="doi">10.1016/j.eclinm.2022.101785</pub-id><pub-id pub-id-type="pmid">36590789</pub-id><pub-id pub-id-type="pmcid">PMC9791950</pub-id></element-citation></ref><ref id="B64-viruses-16-01795"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriazopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Panagopoulos</surname><given-names>P.</given-names></name><name name-style="western"><surname>Metallidis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dalekos</surname><given-names>G.N.</given-names></name><name name-style="western"><surname>Poulakou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gatselis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Karakike</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saridaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Loli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stefos</surname><given-names>A.</given-names></name><etal/></person-group><article-title>An open label trial of anakinra to prevent respiratory failure in COVID-19</article-title><source>Elife</source><year>2021</year><volume>10</volume><elocation-id>e66125</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.66125</pub-id><pub-id pub-id-type="pmid">33682678</pub-id><pub-id pub-id-type="pmcid">PMC8034977</pub-id></element-citation></ref><ref id="B65-viruses-16-01795"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyriazopoulou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Poulakou</surname><given-names>G.</given-names></name><name name-style="western"><surname>Milionis</surname><given-names>H.</given-names></name><name name-style="western"><surname>Metallidis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Adamis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tsiakos</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fragkou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rapti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Damoulari</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fantoni</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial</article-title><source>Nat. Med.</source><year>2021</year><volume>27</volume><fpage>1752</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1038/s41591-021-01499-z</pub-id><pub-id pub-id-type="pmid">34480127</pub-id><pub-id pub-id-type="pmcid">PMC8516650</pub-id></element-citation></ref><ref id="B66-viruses-16-01795"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huet</surname><given-names>T.</given-names></name><name name-style="western"><surname>Beaussier</surname><given-names>H.</given-names></name><name name-style="western"><surname>Voisin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Jouveshomme</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dauriat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lazareth</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sacco</surname><given-names>E.</given-names></name><name name-style="western"><surname>Naccache</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>B&#233;zie</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Laplanche</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Anakinra for severe forms of COVID-19: A cohort study</article-title><source>Lancet Rheumatol.</source><year>2020</year><volume>2</volume><fpage>e393</fpage><lpage>e400</lpage><pub-id pub-id-type="doi">10.1016/S2665-9913(20)30164-8</pub-id><pub-id pub-id-type="pmid">32835245</pub-id><pub-id pub-id-type="pmcid">PMC7259909</pub-id></element-citation></ref><ref id="B67-viruses-16-01795"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>K.</given-names></name></person-group><article-title>Overview of the potential use of fluvoxamine for COVID-19 and long COVID</article-title><source>Discov. Ment. Health</source><year>2023</year><volume>3</volume><elocation-id>9</elocation-id><pub-id pub-id-type="doi">10.1007/s44192-023-00036-3</pub-id><pub-id pub-id-type="pmid">36968793</pub-id><pub-id pub-id-type="pmcid">PMC10029802</pub-id></element-citation></ref><ref id="B68-viruses-16-01795"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsiakalos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ziakas</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Polyzou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Schinas</surname><given-names>G.</given-names></name><name name-style="western"><surname>Akinosoglou</surname><given-names>K.</given-names></name></person-group><article-title>Early Fluvoxamine Reduces the Risk for Clinical Deterioration in Symptomatic Outpatients with COVID-19: A Real-World, Retrospective, before-after Analysis</article-title><source>Microorganisms</source><year>2023</year><volume>11</volume><elocation-id>2073</elocation-id><pub-id pub-id-type="doi">10.3390/microorganisms11082073</pub-id><pub-id pub-id-type="pmid">37630633</pub-id><pub-id pub-id-type="pmcid">PMC10459506</pub-id></element-citation></ref><ref id="B69-viruses-16-01795"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dos Santos Moreira-Silva</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>D.C.M.</given-names></name><name name-style="western"><surname>Thabane</surname><given-names>L.</given-names></name><name name-style="western"><surname>Milagres</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>C.V.Q.</given-names></name><name name-style="western"><surname>de Souza Campos</surname><given-names>V.H.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>A.M.R.</given-names></name><name name-style="western"><surname>de Almeida</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: The TOGETHER randomised, platform clinical trial</article-title><source>Lancet Glob. Health</source><year>2022</year><volume>10</volume><fpage>e42</fpage><lpage>e51</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(21)00448-4</pub-id><pub-id pub-id-type="pmid">34717820</pub-id><pub-id pub-id-type="pmcid">PMC8550952</pub-id></element-citation></ref><ref id="B70-viruses-16-01795"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chanchlani</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chee</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hamilton</surname><given-names>B.</given-names></name><name name-style="western"><surname>Nice</surname><given-names>R.</given-names></name><name name-style="western"><surname>Arkir</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Bewshea</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cipriano</surname><given-names>B.</given-names></name><name name-style="western"><surname>Derikx</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dunlop</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients</article-title><source>J. Crohn&#8217;s Colitis</source><year>2022</year><volume>16</volume><fpage>389</fpage><lpage>397</lpage><pub-id pub-id-type="doi">10.1093/ecco-jcc/jjab153</pub-id><pub-id pub-id-type="pmid">34473254</pub-id><pub-id pub-id-type="pmcid">PMC8499950</pub-id></element-citation></ref><ref id="B71-viruses-16-01795"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amodeo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Persani</surname><given-names>L.</given-names></name><name name-style="western"><surname>Bonomi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cangiano</surname><given-names>B.</given-names></name></person-group><article-title>Use of testosterone replacement therapy to treat long-COVID-related hypogonadism</article-title><source>Endocrinol. Diabetes Metab. Case Rep.</source><year>2024</year><volume>2024</volume><elocation-id>230097</elocation-id><pub-id pub-id-type="doi">10.1530/EDM-23-0097</pub-id><pub-id pub-id-type="pmcid">PMC10959025</pub-id><pub-id pub-id-type="pmid">38520748</pub-id></element-citation></ref><ref id="B72-viruses-16-01795"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarhan</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Warda</surname><given-names>A.E.A.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>H.S.G.</given-names></name><name name-style="western"><surname>Schaalan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Fathy</surname><given-names>S.M.</given-names></name></person-group><article-title>Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>6456</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-33484-6</pub-id><pub-id pub-id-type="pmid">37081046</pub-id><pub-id pub-id-type="pmcid">PMC10116445</pub-id></element-citation></ref><ref id="B73-viruses-16-01795"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yassin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shabsigh</surname><given-names>R.</given-names></name><name name-style="western"><surname>Al-Zoubi</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Aboumarzouk</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Alwani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nettleship</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>D.</given-names></name></person-group><article-title>Testosterone and Covid-19: An update</article-title><source>Rev. Med. Virol.</source><year>2023</year><volume>33</volume><elocation-id>e2395</elocation-id><pub-id pub-id-type="doi">10.1002/rmv.2395</pub-id><pub-id pub-id-type="pmid">36056748</pub-id><pub-id pub-id-type="pmcid">PMC9537909</pub-id></element-citation></ref><ref id="B74-viruses-16-01795"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mostafa-Hedeab</surname><given-names>G.</given-names></name><name name-style="western"><surname>Al-Kuraishy</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Al-Gareeb</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Jeandet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Batiha</surname><given-names>G.E.</given-names></name></person-group><article-title>A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19</article-title><source>Inflammopharmacology</source><year>2022</year><volume>30</volume><fpage>799</fpage><lpage>809</lpage><pub-id pub-id-type="doi">10.1007/s10787-022-00993-1</pub-id><pub-id pub-id-type="pmid">35486310</pub-id><pub-id pub-id-type="pmcid">PMC9051499</pub-id></element-citation></ref><ref id="B75-viruses-16-01795"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sarhan</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Altyar</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Essam Abou Warda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saied</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>H.S.G.</given-names></name><name name-style="western"><surname>Schaalan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Fathy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sarhan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boshra</surname><given-names>M.S.</given-names></name></person-group><article-title>Pentoxifylline Effects on Hospitalized COVID-19 Patients with Cytokine Storm Syndrome: A Randomized Clinical Trial</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>631</elocation-id><pub-id pub-id-type="doi">10.3390/ph16040631</pub-id><pub-id pub-id-type="pmid">37111389</pub-id><pub-id pub-id-type="pmcid">PMC10142327</pub-id></element-citation></ref><ref id="B76-viruses-16-01795"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mateus-Silva</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Brandao-Rangel</surname><given-names>M.A.R.</given-names></name><name name-style="western"><surname>Silva-Reis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olimpio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zamarioli</surname><given-names>L.D.S.</given-names></name><name name-style="western"><surname>Aimbire</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>R.P.</given-names></name></person-group><article-title>A Nutritional Blend Suppresses the Inflammatory Response from Bronchial Epithelial Cells Induced by SARS-CoV-2</article-title><source>J. Diet. Suppl.</source><year>2023</year><volume>20</volume><fpage>156</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1080/19390211.2022.2103607</pub-id><pub-id pub-id-type="pmid">35930300</pub-id></element-citation></ref><ref id="B77-viruses-16-01795"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gomaa</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Abdel-Wadood</surname><given-names>Y.A.</given-names></name><name name-style="western"><surname>Thabet</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Gomaa</surname><given-names>G.A.</given-names></name></person-group><article-title>Pharmacological evaluation of vitamin D in COVID-19 and long COVID-19: Recent studies confirm clinical validation and highlight metformin to improve VDR sensitivity and efficacy</article-title><source>Inflammopharmacology</source><year>2024</year><volume>32</volume><fpage>249</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1007/s10787-023-01383-x</pub-id><pub-id pub-id-type="pmid">37957515</pub-id><pub-id pub-id-type="pmcid">PMC10907442</pub-id></element-citation></ref><ref id="B78-viruses-16-01795"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Looi</surname><given-names>M.K.</given-names></name></person-group><article-title>What is the future for covid drugs and treatments?</article-title><source>BMJ</source><year>2023</year><volume>381</volume><elocation-id>1001</elocation-id><pub-id pub-id-type="doi">10.1136/bmj.p1001</pub-id><pub-id pub-id-type="pmid">37164386</pub-id></element-citation></ref><ref id="B79-viruses-16-01795"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mok</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Ahidjo</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Aw</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>R.C.H.</given-names></name><name name-style="western"><surname>Loe</surname><given-names>M.W.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Evaluation of In Vitro and In Vivo Antiviral Activities of Vitamin D for SARS-CoV-2 and Variants</article-title><source>Pharmaceutics</source><year>2023</year><volume>15</volume><elocation-id>925</elocation-id><pub-id pub-id-type="doi">10.3390/pharmaceutics15030925</pub-id><pub-id pub-id-type="pmid">36986786</pub-id><pub-id pub-id-type="pmcid">PMC10058714</pub-id></element-citation></ref><ref id="B80-viruses-16-01795"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapleton</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Keck</surname><given-names>K.</given-names></name><name name-style="western"><surname>Windisch</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stroik</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Thurman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Zabner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thornell</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Pezzulo</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Klesney-Tait</surname><given-names>J.</given-names></name><name name-style="western"><surname>Comellas</surname><given-names>A.P.</given-names></name></person-group><article-title>Vitamin D-mediated effects on airway innate immunity in vitro</article-title><source>PLoS ONE</source><year>2022</year><volume>17</volume><elocation-id>e0269647</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0269647</pub-id><pub-id pub-id-type="pmid">35666753</pub-id><pub-id pub-id-type="pmcid">PMC9170100</pub-id></element-citation></ref><ref id="B81-viruses-16-01795"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lupse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Calin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jianu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Leucuta</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Briciu</surname><given-names>V.</given-names></name></person-group><article-title>25 Hydroxyvitamin D Serum Concentration and COVID-19 Severity and Outcome-A Retrospective Survey in a Romanian Hospital</article-title><source>Nutrients</source><year>2023</year><volume>15</volume><elocation-id>1227</elocation-id><pub-id pub-id-type="doi">10.3390/nu15051227</pub-id><pub-id pub-id-type="pmid">36904227</pub-id><pub-id pub-id-type="pmcid">PMC10005256</pub-id></element-citation></ref><ref id="B82-viruses-16-01795"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramirez-Sandoval</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Castillos-&#193;valos</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Paz-Cort&#233;s</surname><given-names>A.</given-names></name><name name-style="western"><surname>Santillan-Ceron</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hernandez-Jimenez</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Correa-Rotter</surname><given-names>R.</given-names></name></person-group><article-title>Very Low Vitamin D Levels are a Strong Independent Predictor of Mortality in Hospitalized Patients with Severe COVID-19</article-title><source>Arch. Med. Res.</source><year>2022</year><volume>53</volume><fpage>215</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2021.09.006</pub-id><pub-id pub-id-type="pmid">34711432</pub-id><pub-id pub-id-type="pmcid">PMC8516726</pub-id></element-citation></ref><ref id="B83-viruses-16-01795"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>di Filippo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Uygur</surname><given-names>M.</given-names></name><name name-style="western"><surname>Locatelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nannipieri</surname><given-names>F.</given-names></name><name name-style="western"><surname>Frara</surname><given-names>S.</given-names></name><name name-style="western"><surname>Giustina</surname><given-names>A.</given-names></name></person-group><article-title>Low vitamin D levels predict outcomes of COVID-19 in patients with both severe and non-severe disease at hospitalization</article-title><source>Endocrine</source><year>2023</year><volume>80</volume><fpage>669</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1007/s12020-023-03331-9</pub-id><pub-id pub-id-type="pmid">36854858</pub-id><pub-id pub-id-type="pmcid">PMC9974397</pub-id></element-citation></ref><ref id="B84-viruses-16-01795"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Argano</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mallaci Bocchio</surname><given-names>R.</given-names></name><name name-style="western"><surname>Natoli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scibetta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lo Monaco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corrao</surname><given-names>S.</given-names></name></person-group><article-title>Protective Effect of Vitamin D Supplementation on COVID-19-Related Intensive Care Hospitalization and Mortality: Definitive Evidence from Meta-Analysis and Trial Sequential Analysis</article-title><source>Pharmaceuticals</source><year>2023</year><volume>16</volume><elocation-id>130</elocation-id><pub-id pub-id-type="doi">10.3390/ph16010130</pub-id><pub-id pub-id-type="pmid">36678627</pub-id><pub-id pub-id-type="pmcid">PMC9864223</pub-id></element-citation></ref><ref id="B85-viruses-16-01795"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cicero</surname><given-names>A.F.G.</given-names></name><name name-style="western"><surname>Fogacci</surname><given-names>F.</given-names></name><name name-style="western"><surname>Borghi</surname><given-names>C.</given-names></name></person-group><article-title>Vitamin D Supplementation and COVID-19 Outcomes: Mounting Evidence and Fewer Doubts</article-title><source>Nutrients</source><year>2022</year><volume>14</volume><elocation-id>3584</elocation-id><pub-id pub-id-type="doi">10.3390/nu14173584</pub-id><pub-id pub-id-type="pmid">36079842</pub-id><pub-id pub-id-type="pmcid">PMC9460517</pub-id></element-citation></ref><ref id="B86-viruses-16-01795"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardinali</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Pandi-Perumal</surname><given-names>S.R.</given-names></name></person-group><article-title>Possible Application of Melatonin in Long COVID</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><elocation-id>1646</elocation-id><pub-id pub-id-type="doi">10.3390/biom12111646</pub-id><pub-id pub-id-type="pmid">36358996</pub-id><pub-id pub-id-type="pmcid">PMC9687267</pub-id></element-citation></ref><ref id="B87-viruses-16-01795"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jarrott</surname><given-names>B.</given-names></name><name name-style="western"><surname>Head</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pringle</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Lumbers</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.H.</given-names></name></person-group><article-title>&#8220;LONG COVID&#8221;-A hypothesis for understanding the biological basis and pharmacological treatment strategy</article-title><source>Pharmacol. Res. Perspect.</source><year>2022</year><volume>10</volume><elocation-id>e00911</elocation-id><pub-id pub-id-type="doi">10.1002/prp2.911</pub-id><pub-id pub-id-type="pmid">35029046</pub-id><pub-id pub-id-type="pmcid">PMC8929332</pub-id></element-citation></ref><ref id="B88-viruses-16-01795"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acu&#241;a-Castroviejo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Escames</surname><given-names>G.</given-names></name><name name-style="western"><surname>Figueira</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>de la Oliva</surname><given-names>P.</given-names></name><name name-style="western"><surname>Borobia</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Acu&#241;a-Fern&#225;ndez</surname><given-names>C.</given-names></name></person-group><article-title>Clinical trial to test the efficacy of melatonin in COVID-19</article-title><source>J. Pineal Res.</source><year>2020</year><volume>69</volume><elocation-id>e12683</elocation-id><pub-id pub-id-type="doi">10.1111/jpi.12683</pub-id><pub-id pub-id-type="pmid">32770854</pub-id><pub-id pub-id-type="pmcid">PMC7435535</pub-id></element-citation></ref><ref id="B89-viruses-16-01795"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Artigas</surname><given-names>L.</given-names></name><name name-style="western"><surname>Coma</surname><given-names>M.</given-names></name><name name-style="western"><surname>Matos-Filipe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aguirre-Plans</surname><given-names>J.</given-names></name><name name-style="western"><surname>Farr&#233;s</surname><given-names>J.</given-names></name><name name-style="western"><surname>Valls</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fernandez-Fuentes</surname><given-names>N.</given-names></name><name name-style="western"><surname>de la Haba-Rodriguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olvera</surname><given-names>A.</given-names></name><name name-style="western"><surname>Barbera</surname><given-names>J.</given-names></name><etal/></person-group><article-title>In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0240149</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0240149</pub-id><pub-id pub-id-type="pmid">33006999</pub-id><pub-id pub-id-type="pmcid">PMC7531795</pub-id></element-citation></ref><ref id="B90-viruses-16-01795"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reiter</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Dominquez-Rodriguez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Marik</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Abreu-Gonzalez</surname><given-names>P.</given-names></name></person-group><article-title>Melatonin Inhibits COVID-19-induced Cytokine Storm by Reversing Aerobic Glycolysis in Immune Cells: A Mechanistic Analysis</article-title><source>Med. Drug Discov.</source><year>2020</year><volume>6</volume><elocation-id>100044</elocation-id><pub-id pub-id-type="doi">10.1016/j.medidd.2020.100044</pub-id><pub-id pub-id-type="pmid">32395713</pub-id><pub-id pub-id-type="pmcid">PMC7211589</pub-id></element-citation></ref><ref id="B91-viruses-16-01795"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reynolds</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Dubocovich</surname><given-names>M.L.</given-names></name></person-group><article-title>Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19</article-title><source>J. Pineal Res.</source><year>2021</year><volume>71</volume><elocation-id>e12732</elocation-id><pub-id pub-id-type="doi">10.1111/jpi.12732</pub-id><pub-id pub-id-type="pmid">33759236</pub-id><pub-id pub-id-type="pmcid">PMC8250125</pub-id></element-citation></ref><ref id="B92-viruses-16-01795"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Karri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tay</surname><given-names>N.W.R.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Ah</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>P.Q.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Keh</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Candasamy</surname><given-names>M.</given-names></name></person-group><article-title>Emerging pathways to neurodegeneration: Dissecting the critical molecular mechanisms in Alzheimer&#8217;s disease, Parkinson&#8217;s disease</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>111</volume><fpage>765</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.12.101</pub-id><pub-id pub-id-type="pmid">30612001</pub-id></element-citation></ref><ref id="B93-viruses-16-01795"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sumsuzzman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>Y.</given-names></name></person-group><article-title>Neurocognitive effects of melatonin treatment in healthy adults and individuals with Alzheimer&#8217;s disease and insomnia: A systematic review and meta-analysis of randomized controlled trials</article-title><source>Neurosci. Biobehav. Rev.</source><year>2021</year><volume>127</volume><fpage>459</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1016/j.neubiorev.2021.04.034</pub-id><pub-id pub-id-type="pmid">33957167</pub-id></element-citation></ref><ref id="B94-viruses-16-01795"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Habtemariam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Daglia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sureda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Selamoglu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gulhan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Nabavi</surname><given-names>S.M.</given-names></name></person-group><article-title>Melatonin and Respiratory Diseases: A Review</article-title><source>Curr. Top. Med. Chem.</source><year>2017</year><volume>17</volume><fpage>467</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.2174/1568026616666160824120338</pub-id><pub-id pub-id-type="pmid">27558675</pub-id></element-citation></ref><ref id="B95-viruses-16-01795"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hardeland</surname><given-names>R.</given-names></name></person-group><article-title>Melatonin and inflammation-Story of a double-edged blade</article-title><source>J. Pineal Res.</source><year>2018</year><volume>65</volume><elocation-id>e12525</elocation-id><pub-id pub-id-type="doi">10.1111/jpi.12525</pub-id><pub-id pub-id-type="pmid">30242884</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="viruses-16-01795-f001" orientation="portrait"><label>Figure 1</label><caption><p>Methodological process for selecting Long COVID articles.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-16-01795-g001.jpg"/></fig><fig position="float" id="viruses-16-01795-f002" orientation="portrait"><label>Figure 2</label><caption><p>Available treatments for Long COVID patients and main outcomes.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="viruses-16-01795-g002.jpg"/></fig><table-wrap position="float" id="viruses-16-01795-t001" orientation="portrait"><object-id pub-id-type="pii">viruses-16-01795-t001_Table 1</object-id><label>Table 1</label><caption><p>Representative studies on the impact of different therapeutics on Long COVID.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Author and Country</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Patient Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Intervention and Dosage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Outcomes</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Antihypertensive/ADHD Treatment</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fesharaki-Zadeh A. et al., 2023 (USA) [<xref rid="B2-viruses-16-01795" ref-type="bibr">2</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 patients, aged 21&#8211;73 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Open-label clinical experience</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guanfacine: Initiated at 1 mg orally for 1 month, increased to 2 mg after if well tolerated<break/>N-acetylcysteine: 600 mg orally daily<break/>Arms: Combined treatment No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 8/12 reported cognitive improvements such as enhanced working memory, concentration, and executive functions</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Antioxidant</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hansen K.S. et al., 2023 (Denmark) [<xref rid="B3-viruses-16-01795" ref-type="bibr">3</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121 patients, aged 22&#8211;70 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coenzyme Q10: Daily dose of 500 mg, administered as five 100 mg oral capsules to maximize absorption<break/>Dosing period for 6 weeks, followed by a 4-week washout before switching treatments in a crossover design<break/>Arms: Coenzyme Q10 vs. placebo</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The largest non-significant reduction in symptoms was in neurological and musculoskeletal symptoms, but it was not statistically significant</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Barletta M.A. et al., 2023 (Italy) [<xref rid="B25-viruses-16-01795" ref-type="bibr">25</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">174 patients, aged 18&#8211;81 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective observational study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 mg of alpha lipoic acid/Coenzyme Q10 each twice daily for 2 months<break/>Arms: 116 patients on combination vs. 58 patients control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 53.5% of treated patients achieved complete response (a &#8805; 50% reduction in Fatigue Severity Scale) vs. 3.5% in the control</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Antidiabetic</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bramante C.T. et al., 2024 (USA) [<xref rid="B26-viruses-16-01795" ref-type="bibr">26</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">999 patients, aged 30&#8211;85 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metformin: 500 mg on the first day, 500 mg twice until day five, and 500 mg or 1000 mg morning/evening, respectively, until day 14<break/>Fluvoxamine: 50 mg the first day, and 50 mg twice daily until day 14<break/>Ivermectin: A median dose of 430 &#181;g/kg/day for 3 days<break/>Arms: Each drug was compared to a placebo group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long COVID reduction by 42% due to metformin<break/>Long COVID 65% reduction if metformin treatment started within four days</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bramante C.T. et al., 2023 (USA) [<xref rid="B27-viruses-16-01795" ref-type="bibr">27</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1431 patients, aged 30&#8211;85 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metformin: 500 mg on the first day, 500 mg twice until day five, and 500 mg or 1000 mg morning/evening, respectively, until day 14<break/>Ivermectin: Up to 470 &#956;g/kg daily for 3 days.<break/>Fluvoxamine: Once 50 mg the first day, and 50 mg twice daily until day 14<break/>Arms: Each drug was compared to a placebo group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Long COVID<break/>metformin reduced the rate 41%<break/>Until day 300 of 6.3% vs. 10.4% for controls developed Long COVID<break/>Administered within 3 days of symptom onset, it provided an even greater reduction in long COVID risk, with an HR of 0.37 (95% CI 0.15&#8211;0.95)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Immunomodulator</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bonilla H. et al., 2023 (USA) [<xref rid="B28-viruses-16-01795" ref-type="bibr">28</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 patients, aged 34&#8211;59 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective observational study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-dose naltrexone: Average of 2 mg daily, median duration of treatment was 143 days<break/>Arms: Combined treatment No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue significant reduction (<italic toggle="yes">p</italic> = 0.013).<break/>Post-exertional malaise improved (<italic toggle="yes">p</italic> = 0.010).<break/>Unrefreshing sleep and abnormal sleep patterns were significantly improved (<italic toggle="yes">p</italic> = 0.010 and <italic toggle="yes">p</italic> = 0.016, respectively)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isman A. et al., 2024 (USA) [<xref rid="B29-viruses-16-01795" ref-type="bibr">29</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 patients, aged 28&#8211;69 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational, open-label pilot study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-dose naltrexone: 4.5 mg/day, the dose was gradually increased over the first 9 days<break/>NAD+: Using iontophoresis patches, delivering 400 mg of NAD+ weekly<break/>Interventions lasted 12 weeks<break/>Arms: Combined treatment No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-36 score increased from 36.5 to 52.1 at 12 weeks, showing a significant improvement (<italic toggle="yes">p</italic> &lt; 0.0001)<break/>Both physical and mental fatigue scores showed substantial improvement</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Tamariz L. et al., 2023 (USA) [<xref rid="B30-viruses-16-01795" ref-type="bibr">30</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">108 patients, aged</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective cohort study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LDN, amitriptyline, duloxetine<break/>Arms: LDN vs. physical therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Relative hazard of improvement for LDN group was 5.04 (95% CI: 1.22&#8211;20.77) vs. control<break/>Fatigue and pain were improved for LDN group</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">O&#8217;Kelly B. et al., 2022 (Ireland) [<xref rid="B31-viruses-16-01795" ref-type="bibr">31</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">52 patients, aged 33&#8211;49 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Interventional study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 mg of LDN daily in the first month and 2 mg daily in the second month.<break/>Arms: No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Statistical improvement in multiple metrics including fatigue levels, measurements of pain, cognitive performance, and sleep quality</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Milne A. et al., 2023 (UK) [<xref rid="B32-viruses-16-01795" ref-type="bibr">32</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">198 patients, aged 51&#8211;72 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational case&#8211;control study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone: 39 patients received 6 mg of oral dexamethasone once daily during their hospital stay, median duration of treatment was 7 days<break/>Arms: Dexamethasone vs. control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Most significant reductions (8-month follow-up) were in fatigue (33% for dexamethasone vs. 52% in for placebo, <italic toggle="yes">p</italic> = 0.07) and insomnia (15% in the dexamethasone group vs. 39% in control group, <italic toggle="yes">p</italic> = 0.01)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Badenes Bonet D. et al., 2023 (Spain) [<xref rid="B33-viruses-16-01795" ref-type="bibr">33</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1966 patients, mean age 56.4 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One-year prospective observational study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone: 6 mg daily for 10 days <break/>Arms: Dexamethasone vs. control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The median duration for symptoms for patients treated with dexamethasone was 133 days (compared to 271 days for those not treated with dexamethasone)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hogeweg M. et al., 2023 (Germany) [<xref rid="B34-viruses-16-01795" ref-type="bibr">34</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30 patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Retrospective case&#8211;control study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intravenous immunoglobulins:<break/>3&#8211;4 monthly courses of IVIg, administered at a dose of 0.5 g/kg (Group A)<break/>Inhaled glucocorticoids:<break/>budesonide inhalation at a dosage of 0.2 mg twice daily (Group B)<break/>Supportive Therapy:<break/>Mon-pharmacological treatments managing post-COVID symptoms (Group C)<break/>Arms: No combinations and compared to supportive therapy</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptom Improvement (ISARIC Score):<break/>Change in score was significantly higher in group A (&#8722;5.44 &#177; 2.35; <italic toggle="yes">p</italic> &lt; 0.001) compared to Group B (&#8722;0.3 &#177; 0.82) and Group C (&#8722;0.89 &#177; 0.93)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Thompson J.S. et al., 2022 (USA) [<xref rid="B35-viruses-16-01795" ref-type="bibr">35</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 patients, aged 34&#8211;79 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Observational case study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">The standard treatment involved 0.5 g/kg of IVIg bi-weekly for a trial period of 3 months.<break/>Arms: IVIg vs. untreated patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Six patients received IVIg treatment, and all reported significant to remarkable improvements, particularly in cognitive dysfunction, fatigue, and pulmonary issues</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Statin</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Khosravi A et al., 2023 (Iran) [<xref rid="B37-viruses-16-01795" ref-type="bibr">37</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">858 patients, aged 18&#8211;85 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective cohort study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Atorvastatin 20 mg daily or Rosuvastatin 10 mg daily for at least 15 days<break/>Arms: Statin vs. control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MACE risk<break/>After median follow-up of 13 months statins (HR: 0.831; 95% CI: 0.529&#8211;0.981)</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Other</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liu T.H. et al., 2023 (China) [<xref rid="B38-viruses-16-01795" ref-type="bibr">38</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33,908 patients, aged 18&#8211;85 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One-year retrospective cohort analysis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omega-3 polyunsaturated fatty acids supplements<break/>Omega-3 intake was within 6 months prior to their COVID-19 diagnosis<break/>Arms: Omega-3 vs. no use</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Depression: HR = 0.828; (95% CI:0.714&#8211;0.960)<break/>Myalgia: HR = 0.606; (95% CI: 0.417&#8211;0.880)<break/>Cough: HR = 0.814; (95% CI: 0.683 to 0.970)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Izzo R. et al., 2022 (Italy) [<xref rid="B39-viruses-16-01795" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1390 patients, aged 18&#8211;90 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Nationwide survey-based observational study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-Arginine: 1.66 g (two vials/day).<break/>Vitamin C: 500 mg of liposomal Vitamin C daily.<break/>Patients in the alternative treatment group received a multivitamin combination<break/>Arms: Combined treatment. No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fatigue: Absent in 94.9% of patients in the L-Arginine + Vitamin C group compared to 0.4% in the control group<break/>Dyspnea: Absent in 74.2% of patients in the L-Arginine + Vitamin C group compared to 5.4% in the control group</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Jaeger B.R. et al., 2023 (Germany) [<xref rid="B40-viruses-16-01795" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 patients, aged 23&#8211;63 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pilot study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">H.E.L.P. Apheresis: In each session, 400,000 units of unfractionated heparin were used in the process<break/>During each treatment, between 2 and 4 L of blood were processed. The treatment lasted between 2 and 4 h per session<break/>Arms: No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 16 patients experienced significant symptom improvement<break/>Follow-up between 6 and 10 months after the last treatment, 15 patients maintained their improvements</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Achleitner M. et al., 2023 (Germany) [<xref rid="B41-viruses-16-01795" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 patients<break/>Mean age of 49.7 years for men and 44.9 years for women</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prospective observational study</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Apheresis: Each session lasted 114 min on average, and 8000 units of heparin were used per treatment.<break/>Arms: No control group</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A total of 70% of the patients reported a significant improvement in symptoms such as fatigue, post-exertional malaise, and brain fog</td></tr></tbody></table><table-wrap-foot><fn><p>IVIg: intravenous immunoglobulins; LDN: low-dose naltrexone; RCT: Randomized Controlled Trial; MACE: Major Adverse Cardiovascular Event; HR: Hazard Ratio; CI: Confidence Intervals.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01795-t002" orientation="portrait"><object-id pub-id-type="pii">viruses-16-01795-t002_Table 2</object-id><label>Table 2</label><caption><p>Advanced, in-progress pharmacotherapy trials on Long COVID.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Trial Number and Estimated Completion Date</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Patient Population</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Study Design</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Intervention and Dosage</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#D0CECE" rowspan="1" colspan="1">Outcome Measure</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Immunomodulator</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05926505">NCT05926505</ext-link><break/>(August 2025)<break/>[<xref rid="B42-viruses-16-01795" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">182 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2&#8211;3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Anakinra injected subcutaneously as 100 mg once daily for 4 weeks<break/>Placebo injected subcutaneously once daily for 4 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Score of PACS progression reversal<break/>Changes in concentration of cytokines produced</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05513560">NCT05513560</ext-link><break/>(December 2025)<break/>[<xref rid="B43-viruses-16-01795" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2&#8211;3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ibudilast<break/>10 mg pills, 2 pills twice per day<break/>Pentoxifylline<break/>400 mg pill 3 times per day<break/>Placebo matching ibudilast OR pentoxifylline dosing schedule</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SF-36 physical component score</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05220280">NCT05220280</ext-link><break/>(December 2025)<break/>[<xref rid="B44-viruses-16-01795" ref-type="bibr">44</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">400 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 4, Randomized, Open Label</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oral imatinib 400 mg tablet once a day for 14 days<break/>Infliximab as a single infusion of 5 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Health-related quality of life<break/>Mortality</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Anti-depressant/Antidiabetic</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05874037">NCT05874037</ext-link><break/>(May 2025)<break/>[<xref rid="B45-viruses-16-01795" ref-type="bibr">45</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">300 patients<break/>25 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2&#8211;3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">An amount of 25 mg/50 mg/100 mg fluvoxamine doses to assess impact on each patient<break/>Customized dose of fluvoxamine vs. placebo for 16 weeks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Patient-reported assessments on improvement of Long COVID symptoms<break/>Biomarkers of underlying inflammatory pathophysiology</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06128967">NCT06128967</ext-link><break/>(May 2025)<break/>[<xref rid="B46-viruses-16-01795" ref-type="bibr">46</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1500 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fluvoxamine Maleate 100 mg per pill<break/>Oral 750 mg Metformin extended release <break/>Placebo matching dosing schedules</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Improvement on Fatigue Severity Score Scale</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin;background:#D0CECE" rowspan="1">
<bold>Therapeutic Category: Other</bold>
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT05795816">NCT05795816</ext-link><break/>(November 2025)<break/>[<xref rid="B47-viruses-16-01795" ref-type="bibr">47</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">150 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3 RCT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Testofen: Twice daily 300 mg dose<break/>Microcrystalline cellulose:<break/>Same dosing schedule as testofen</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Change in energy and fatigue</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT06166030">NCT06166030</ext-link><break/>(December 2024)<break/>[<xref rid="B48-viruses-16-01795" ref-type="bibr">48</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">58 patients<break/>18 years and older</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3 Non-Randomized, Open Label</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">One month administration of ImmuneRecov</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lung function tests and immune reaction</td></tr></tbody></table><table-wrap-foot><fn><p>RCT: Randomized Controlled Trial.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="viruses-16-01795-t003" orientation="portrait"><object-id pub-id-type="pii">viruses-16-01795-t003_Table 3</object-id><label>Table 3</label><caption><p>Treatments for Long COVID impacting cognitive symptoms.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Treatment</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">% Improvement in Cognitive Symptoms</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin;background:#E7E6E6" rowspan="1" colspan="1">Mechanism</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guanfacine + NAC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Strengthens prefrontal cortex connectivity, reduces oxidative stress</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LDN</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">54%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modulates immune response, reduces chronic inflammation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CoQ10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Moderate, non-significant improvement in fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Supports mitochondrial function, reduces oxidative stress</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IVIg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70&#8211;75%</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Neutralizes autoantibodies, reduces neuro-inflammation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omega-3 Fatty Acids</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modest, non-significant improvement in mood, myalgia</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduces inflammation, supports endothelial function</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dexamethasone</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">33% reduction in fatigue</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduces systemic inflammation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Metformin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Preventative (up to 63% reduction)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Reduces inflammation, modulates immune response</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapeutic Apheresis</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">70% reported symptom improvement</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Removes inflammatory cytokines and autoantibodies, reduces immune dysregulation</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">L-Arginine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">94.9% absence of fatigue, improvement in oxygen delivery</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhances nitric oxide production, improves endothelial function, reduces inflammation</td></tr></tbody></table><table-wrap-foot><fn><p>NAC: N-acetylcysteine; LDN: low-dose naltrexone; CoQ10: Coenzyme Q10; IVIg: intravenous immunoglobulin.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>